AU748237B2 - Methods for cleaving DNA with nucleotide integrases - Google Patents
Methods for cleaving DNA with nucleotide integrases Download PDFInfo
- Publication number
- AU748237B2 AU748237B2 AU66762/98A AU6676298A AU748237B2 AU 748237 B2 AU748237 B2 AU 748237B2 AU 66762/98 A AU66762/98 A AU 66762/98A AU 6676298 A AU6676298 A AU 6676298A AU 748237 B2 AU748237 B2 AU 748237B2
- Authority
- AU
- Australia
- Prior art keywords
- intron
- substrate
- rna
- nucleotide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002773 nucleotide Substances 0.000 title claims description 406
- 125000003729 nucleotide group Chemical group 0.000 title claims description 405
- 108010061833 Integrases Proteins 0.000 title claims description 194
- 238000000034 method Methods 0.000 title claims description 123
- 102000012330 Integrases Human genes 0.000 title description 12
- 239000000758 substrate Substances 0.000 claims description 384
- 108091029499 Group II intron Proteins 0.000 claims description 211
- 238000003776 cleavage reaction Methods 0.000 claims description 205
- 230000007017 scission Effects 0.000 claims description 205
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 195
- 108090000623 proteins and genes Proteins 0.000 claims description 193
- 102100034343 Integrase Human genes 0.000 claims description 191
- 102000004169 proteins and genes Human genes 0.000 claims description 185
- 108020004414 DNA Proteins 0.000 claims description 177
- 238000002360 preparation method Methods 0.000 claims description 106
- 102000039446 nucleic acids Human genes 0.000 claims description 91
- 108020004707 nucleic acids Proteins 0.000 claims description 91
- 150000007523 nucleic acids Chemical class 0.000 claims description 91
- 101001003004 Anas platyrhynchos Ferritin heavy chain Proteins 0.000 claims description 83
- 102000053602 DNA Human genes 0.000 claims description 72
- 239000002245 particle Substances 0.000 claims description 70
- 230000004570 RNA-binding Effects 0.000 claims description 52
- 230000000295 complement effect Effects 0.000 claims description 41
- 238000009396 hybridization Methods 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 230000000052 comparative effect Effects 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 114
- 239000000203 mixture Substances 0.000 description 78
- 238000009472 formulation Methods 0.000 description 69
- 102000004389 Ribonucleoproteins Human genes 0.000 description 64
- 108010081734 Ribonucleoproteins Proteins 0.000 description 64
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 64
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 63
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 41
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 41
- 230000035772 mutation Effects 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 28
- 210000003470 mitochondria Anatomy 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000002438 mitochondrial effect Effects 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 108700028369 Alleles Proteins 0.000 description 14
- 239000011543 agarose gel Substances 0.000 description 14
- 238000011144 upstream manufacturing Methods 0.000 description 14
- 101150018198 COX1 gene Proteins 0.000 description 13
- 101150043980 COXI gene Proteins 0.000 description 13
- 101001126471 Homo sapiens Plectin Proteins 0.000 description 13
- 102100030477 Plectin Human genes 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 108091092195 Intron Proteins 0.000 description 12
- 229930006000 Sucrose Natural products 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 12
- 239000005720 sucrose Substances 0.000 description 12
- 108020004682 Single-Stranded DNA Proteins 0.000 description 11
- 108091081021 Sense strand Proteins 0.000 description 10
- 238000002741 site-directed mutagenesis Methods 0.000 description 9
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 241000194035 Lactococcus lactis Species 0.000 description 7
- 101150079116 MT-CO1 gene Proteins 0.000 description 7
- 235000014897 Streptococcus lactis Nutrition 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 101100232406 Arabidopsis thaliana IBS1 gene Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108020005196 Mitochondrial DNA Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108020004418 ribosomal RNA Proteins 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000003763 chloroplast Anatomy 0.000 description 3
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 101150043593 ltrBE2 gene Proteins 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 2
- 241000221962 Neurospora intermedia Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100037681 Protein FEV Human genes 0.000 description 2
- 101710198166 Protein FEV Proteins 0.000 description 2
- 244000206963 Saccharomyces cerevisiae var. diastaticus Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000005188 flotation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241000192685 Calothrix Species 0.000 description 1
- 241001464430 Cyanobacterium Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 101710086053 Putative endonuclease Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108020003564 Retroelements Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- -1 ligations Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 98/38337 PCT/US98/03990 METHODS FOR CLEAVING DNA WITH NUCLEOTIDE INTEGRASES
BACKGROUND
In recent years, a number of methods hav La ~u-j iJauuiai ng UNA. SonJof these methods employ biomolecules to cut or cleave DNA, which in some instances renders the substrate. DNA nonfunctional. Other methods employ biomolecules to facilitate insertion of new pieces of nucleic acid into the cleavage site of the DNA substrate. The insertion of new segments of nucleic acid into the cleavage sites of the DNA substrate changes the characteristics of the RNA or protein molecules encoded by the substrate DNA molecules.
Accordingly, the biomolecules which catalyze the cleavage of DNA substrates or the insertion of new nucleic acid molecules into the DNA substrates are useful tools for genetic engineering, for analytical studies and for diagnostic studies. One such molecule used for cleaving DNA substrates is the restriction endonuclease.
Restriction endonucleases are enzymatic proteins that cleave double-stranded DNA. Such endonucleases recognize specific nucleotide sequences in double-stranded DNA, and cleave both strands within or near the specific recognition site. Such specificity renders the restriction endonucleases important tools in the controlled fragmentation of double-stranded DNA. Restriction endonucleases are also useful analytical tools for determining whether certain sequences are present in substrate DNA and in genomic sequencing studies.
However, restriction endonucleases only cleave DNA substrates; they do not insert new nucleic acid molecules into the cleaved DNA substrate. Accordingly, another biomolecule is needed to insert new pieces of DNA or RNA into the double-stranded DNA.
Ribozymes are catalytic RNA molecules that cleave RNA and, in certain circumstances, that insert new pieces of RNA into the cleavage site of the RNA substrate. Unfortunately, ribozymes have not been particularly useful for cleaving single-stranded DNA substrates or double-stranded DNA substrates. Ribozymes cut singlestranded DNA only under extreme conditions of elevated temperatures and high concentrations of magnesium.
Ribozymes can be used to cleave double-stranded DNA only after the DNA is denatured and separated into two pieces of single-stranded DNA. Moreover, ribozymes have limited use in systems containing ribonucleases.
Accordingly, it is desirable to have new methods that employ a new tool that is capable of cleaving double-stranded DNA molecules, single-stranded DNA molecules, and single-stranded RNA molecules at specific sites. Methods which employ a new biomolecule capable of cleaving RNA molecules, single-stranded DNA molecules and double-stranded DNA molecules at specific sites and simultaneously inserting a new nucleic acid molecule into the cleavage site are especially desirable.
SUMMARY OF THE INVENTION The present invention provides new methods, employing a nucleotide integrase, for cleaving singlestranded RNA substrates, single-stranded DNA substrates, and double-stranded DNA substrates at specific sites and for inserting nucleic acid molecules into the cleaved substrate. The nucleotide integrase is a ribonucleoprotein particle comprising a group II intron RNA and a group II intron-encoded protein, which is bound to the group II intron RNA.
2 Disclosed herein is the use of a nucleotide integrase to cleave one strand, hereinafter referred to as the "top strand" of a double stranded DNA substrate. As denoted herein, nucleotides that are located upstream of the cleavage site on the top strand have a position relative to the cleavage site, and nucleotides that are located downstream of the cleavage site have a position relative to the cleavage site. Thus, the cleavage site is located between nucleotides -1 and +1 on the top strand of the double-stranded DNA substrate. The top strand of the substrate comprises a first intron RNA binding sequence, hereinafter referred to as the "IBS I" sequence and a second intron RNA binding sequence, hereinafter referred to as the "IBS2" sequence. The MSI sequence and EBS2 sequence lie in a region which extends from about position -1 to about position -14 relative to the cleavage site. The first 10 to 12 pairs of nucleotides that lie upstream of IEBS2 and EBSI, i.e. from about position -12 relative to the cleavage site to about position -24 relative to the cleavage site are hereinafter collectively referred to as "the first sequence element". The first 10 to 12 pairs of nucleotide that lie downstream of the cleavage site are hereinafter collectively referred to as 'the second sequence element".
Thus, disclosed herein is a method which comprises the steps of. providing a nucleotide integrase comprising a group 11 intron RNA having two hybridizing sequences, "EBS1 and "EBS2", that are capable of hybridizing with the IBSI sequence and EBS2 sequence, respectively, on the top strand of the DNA substrate, and a group 11-intron encoded protein which binds to at least one nucleotide in the first sequence element of the substrate; and reacting the nucleotide integrase with the double-stranded DNA substrate under conditi ons that permit the nucleotide integrase to cleave the top strand of the DNA substrate and to insert the group II intron RNA into the cleavage site. Preferably, the nucleotide immediately preceding the first nucleotide of the EB S 1 sequence on the group II V. 25 intron RNA, hereinafter referred to as the 8 nucleotide is complementary to the nucleotide at +1 on the top strand of the substrate, hereinafter referred to as the 6' nucleotide. The EBSI sequence of the group 11 intron RNA comprises from about 5 to 7 nucleotides and has substantial complementarity with the nucleotides at positions -1 to about -5 or about -7 on the top strand of the DNA substrate. The EBS2 sequence comprises from about 4 to 7 nucleotides and has substantial complementarity with the nucleotides at positions from about-6 to about -14 on the top strand of the DNA substrate.
00 0.
.0 Also disclosed herein is a method which employs a nucleotide integrase to cleave both strands of a double-stranded DNA substrate. The method comprises the steps ofproviding a nucleotide integrase comprising a group 11 intron RNA having two hybridizing sequences, EBS I and EBS2, that are capable of hybridizing with two intron RNA binding sequences, EBS I and EBS2, on the top strand of the substrate, and a group 11-intron encoded protein that is capable of binding to at least one nucleotide in the first sequence element and to at least one nucleotide in a second sequence element in the recognition site of the RA4/ A4/ substrate; and reacting the nucleotide integrase with the double-stranded DNA substrate C08506 3 such that the nucleotide integrase cleaves both strands of the DNA substrate and inserts the group II intron RNA into the cleavage site of the top strand. Preferably, the 8 nucleotide of the group II intron RNA is complementary to the 8' nucleotide on the top strand of the substrate.
Further disclosed herein is the use of a nucleotide integrase for cleaving a singlestranded nucleic acid substrate and for inserting the group II intron RNA of the nucleotide integrase into the cleavage site. The method comprises the steps of: providing a nucleotide integrase having two hybridizing sequences, EBS1 and EBS2, that are capable of hybridizing with two intron RNA-binding sequences, IBS1 and IBS2, on the singlestranded substrate, and a group II intron encoded protein; and reacting the nucleotide integrase with the single stranded nucleic acid substrate for a time and at a temperature sufficient to allow the nucleotide integrase to cleave the substrate and to attach the group II intron RNA molecule thereto. The EBS1 sequence of the group II intron RNA comprises from about 5 to 7 nucleotides that have substantial complementarity with the nucleotides at is positions -1 to about -5 or about -7 relative to the putative cleavage site. The EBS2 sequence comprises from about 4 to 7 nucleotides that have substantial complementarity with the nucleotides at positions from about -6 to about -14 relative to the putative cleavage site. Preferably, the 6 nucleotide of the group II intron RNA is complementary to the 6' nucleotide on the top strand of the substrate.
Also disclosed herein is a method of determining whether a nucleic acid comprises a particular recognition site. The method comprises the steps of providing a nucleotide integrase capable of cleaving a nucleic acid comprising a particular recognition site; reacting the nucleotide integrase with the nucleic acid; and assaying for cleavage of the nucleic acid, wherein cleavage of the nucleic acid indicates that the nucleic acid comprises 25 the recognition site.
Thus, according to a first embodiment of the invention, there is provided a method of enhancing cleavage of a double stranded DNA substrate by a nucleotide integrase at a cleavage site, said substrate having a recognition site, said method comprising the following steps: 30 providing a nucleotide integrase comprising: a modified group II intron RNA having a first hybridization sequence capable of hybridizing with a first intron RNA binding sequence of one strand of the DNA substrate and a second hybridization sequence capable of hybridizing with a second RNA binding sequence on said one strand of the substrate, said modified group II intron RNA 35 comprising a 6 nucleotide that is complementary to a 6' nucleotide on said one strand of the substrate, said 6' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein capable of binding with at least one Rnucleotide in a first sequence element in the recognition site of the substrate, said group II S intron-encoded protein being bound to said modified group II intron RNA; C08506 3a providing a substrate whose recognition site comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived; and reacting the nucleotide integrase with the substrate to permit the nucleotide integrase to cleave said one strand of the DNA substrate and to insert the modified group II intron RNA into the cleavage site.
According to a second embodiment of the invention, there is provided a method of enhancing cleavage of a single-stranded nucleic acid substrate with a nucleotide integrase at a cleavage site comprising the following steps: providing a nucleotide integrase comprising: a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein bound to said modified group II intron RNA; and reacting the nucleotide integrase with the substrate to permit the nucleotide integrase to cleave the nucleic acid substrate and to insert the modified group II intron RNA into the cleavage site.
According to a third embodiment of the invention, there is provided a method of enhancing cleavage of both strands of a double-stranded DNA substrate by a nucleotide integrase, said method comprising the following steps: 25 providing a nucleotide integrase comprising: a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on one strand of the DNA substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said one strand of the DNA substrate, said modified group II 30 intron RNA comprising a 6 nucleotide that is complementary to a 6' nucleotide on said one strand of the substrate, said 6' nucleotide being located at position +1 relative to the Scleavage site; and (ii) a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence o~ 35 element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA; providing a substrate whose recognition site comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived; and C08506 3b reacting the nucleotide integrase with the substrate for a time and at a temperature sufficient to permit the nucleotide integrase to cleave both strands of the DNA substrate and to insert the modified group II intron RNA into the cleavage site on said one strand.
According to a fourth embodiment of the invention, there is provided a reconstituted nucleotide integrase preparation for enhanced cleavage of a nucleic acid substrate at a cleavage site, said preparation comprising: a modified group II intron RNA having a first hybridization sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridization sequence capable of hybridizing with a second RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 6' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein; (iii) a reconstituted nucleotide integrase that cleaves a nucleic acid substrate at a specific site, said group II intron-encoded protein being bound to said modified group II intron RNA.
According to a fifth embodiment of the invention, there is provided a method for making a reconstituted nucleotide integrase preparation for enhanced cleavage of a nucleic acid substrate at a cleavage site, said method comprising the following steps: providing an exogenous RNA molecule which comprises a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid V. 25 substrate, said modified group II intron RNA comprising a 8 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 6' nucleotide being located at position +1 relative to the cleavage site; providing an RNA-protein complex comprising: S. a group II intron-encoded protein capable of binding to at least one 30 nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA, said protein comprising an X domain and a Zn domain; and (ii) RNA that is free of group II intron RNA having a sequence that encodes :said protein; and 35 combining said exogenous RNA with said RNA-protein complex to form a reconstituted nucleotide integrase preparation. Reconstituted nucleotide integrase preparations made by such method, and methods of enhancing cleavage of nucleic acid substrates using such preparations are also provided.
C08506 3c According to a sixth embodiment of the invention, there is provided a reconstituted RNP particle for enhanced cleavage of a nucleic acid substrate at a cleavage site, said particle comprising: a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 8' nucleotide on the substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; and a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA.
According to a seventh embodiment of the invention, there is provided a method for making a reconstituted RNP particle for enhanced cleavage of a nucleic acid substrate at a cleavage site, said method comprising the following steps: providing an exogenous RNA molecule which comprises a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 8 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; providing an RNA-protein complex comprising: S 25 a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA, said protein comprising an X domain and a Zn domain; and 0 (ii) RNA that is free of group II intron RNA having a sequence that encodes 30 said protein; and combining said exogenous RNA with said RNA-protein complex to form a S. reconstituted RNP particle. Reconstituted RNP particles made by such method, and methods of enhancing cleavage of nucleic acid substrates using such particles are also provided.
35 Brief Description of the Drawings Figure 1 is a diagram showing the interaction between the EBS sequences of a group II intron RNA of the second intron of the S. cerevisiae mitochondrial COX1 gene, hereinafter referred to as the "aI2 intron" RNA and the IBS sequences of a DNA substrate.
y The cleavage site in the substrate is represented by an arrow.
C08506 3d Figure 2 is a diagram depicting the nucleotide sequence of the aI2 intron RNA, SEQ.ID.NO.1 and the nucleotide sequence of the group II intron RNA of the first intron of the S. cerevisiae mitochondrial COX1 gene, hereinafter referred to as the "all intron" RNA, SEQ.ID.NO.2. Markings above the sequence identify the position of the EBS1 sequence and the EBS2 sequence of the wild-type all intron RNA and the wild-type aI2 intron RNA.
Figure 3 is a chart depicting the sequence of a DNA substrate cleaved by a nucleotide integrase comprising a wild-type aI2 intron RNA and the protein encoded thereby and the position of the point mutations made in this sequence.
Figure 4 is a graph showing the relative extent of cleavage of the substrates having mutations in the first sequence element by a nucleotide integrase comprising a wild-type al2 intron RNA and the protein encoded thereby.
Figure 5 is a graph showing the relative extent of cleavage of the substrates having mutations in the second sequence element by a nucleotide integrase comprising a wild-type al2 intron RNA and the protein encoded by the aI2 intron RNA.
is Figure 6 is a chart depicting the sequence of a DNA substrate cleaved by a nucleotide integrase comprising a wild-type all intron RNA, and the protein encoded by the all intron RNA and the position of the mutations made in this sequence.
b i C08506 WO 98/38337 PCT/US98/03990 Figure 7 is a graph showing the relative extent of cleavage of the substrates having mutations upstream of the cleavage site by a nucleotide integrase comprising a wild-type all intron RNA and the protein encoded thereby.
Figure 8 is a chart depicting the sequence of a DNA substrate cleaved by a nucleotide integrase comprising a wild-type group II intron RNA of the Lactococcus lactis ItrB gene, hereinafter referred to as the "Ll.ltrB intron" RNA, and the protein encoded thereby, hereinafter referred to as the ItrA protein.
Figure 9 is a graph showing the relative extent of cleavage of the substrates having mutations in the first sequence element by a nucleotide integrase comprising a wild-type Ll.ltrB intron RNA and the ItrA protein.
Figure 10 shows the Ll.ltrB intron DNA sequence and portions of the nucleotide sequence of the flanking exons ItrBEl and ltrBE2, SEQ.ID.NO.5, the nucleotide sequence of the open reading frame, of the Ll.ltrB intron SEQ. ID. NO. 6 and the amino acid sequence of the ItrA protein, SEQ.ID.NO. 7.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides new methods that employ a nucleotide integrase for manipulating DNA and RNA substrates.
One method uses a nucleotide integrase to cleave one strand, hereinafter referred to as the top strand, of a double-stranded DNA at a specific site and to concomitantly attach a nucleic acid molecule, which comprises an RNA molecule, to the cleaved strand at the cleavage site. The DNA substrate has a recognition site which comprises a first intron RNA binding sequence (IBSI) that is located on the top strand of the substrate and upstream of the cleavage site and a second intron RNA binding sequence (IBS2) that is located on the top strand of the DNA substrate and upstream of the IBSI sequence. The recognition site also comprises a first sequence element that is located upstream of the IBS2 sequence. The first sequence element comprises from about 10 to 12 pairs of nucleotides.
The method of cleaving the top strand of a double-stranded DNA substrate comprises the steps of: providing a nucleotide integrase comprising a group II intron RNA having an EBSI sequence and an EBS2 sequence that are capable of hybridizing with the IBS1 sequence and the IBS2, respectively on the top strand of the DNA substrate, and a group II-intron encoded protein capable of binding to at least one nucleotide in the first sequence element: and reacting the nucleotide integrase with the double-stranded DNA substrate for a time and at a temperature sufficient to permit the nucleotide integrase to cleave the top strand of the DNA substrate and to insert the group II intron RNA into the cleavage site. Preferably, the group II intron-encoded protein binds to a plurality of nucleotides in the first sequence element.
The nucleotide integrase employed in this method comprises a group II intron-encoded protein bound to an excised group II intron RNA. The EBSI sequence and EBS2 sequence of the group II intron RNA have at least 80%, preferably 90%, more preferably full complementarity with the IBS1 sequence and IBS2 sequence, respectively, that are on the top strand of the substrate. The group II intron-encoded protein comprises an RT domain, an X domain, and the non-conserved portion of the Zn domain.
EBS1 is located in domain I of the group II intron RNA and comprises from about 5 to 7 nucleotides that are capable of hybridizing to the nucleotides of the IBS 1 sequence of the substrate. EBS2 is located in domain I of 'ti I WO 98/38337 PCT/US98/03990 the group II intron RNA upstream of EBSI and comprises from about 4 to 7 nucleotides that are capable of hybridizing to the nucleotides of IBS2 sequence of the substrate. If the nucleotides of the EBSI and EBS2 sequences of the group II intron RNA are not at least 80% complementary to the nucleotides of the IBS1 or IBS2 sequences, respectively, then the group II intron RNA is modified to increase the complementarity between the EBS and IBS sequences. As shown in Fig. I the IBS1 sequence of the substrate is upstream of the cleavage site and the IBS2 sequence of the substrate is upstream of the IBSI sequence.
In order to cleave the substrate efficiently, it is preferred that the nucleotide, 8, which immediately precedes the first nucleotide of EBSI of the group II intron RNA, be complementary to the nucleotide at +1 in the top strand. Thus, if the 6 nucleotide is not complementary to the nucleotide at +1 on the top strand of the substrate, the group II intron RNA is modified to contain a delta nucleotide which is complementary to the nucleotide at +1 on the top strand of the substrate. The nucleotide integrase is then reacted with the substrate. Suitable nucleotide integrases for use in this method include, for example the aI2 nucleotide integrase, the all nucleotide integrase, and the ItrA nucleotide integrase.
The a12 integrase comprises a wild-type or modified group II intron RNA of the second intron of the S. cerevisiae mitochondrial COXI gene, hereinafter referred to as the "aI2 intron" RNA, bound to a wild-type or modified a12 intron encoded-protein. The sequence of the wild-type a12 intron RNA is depicted in Fig. 1 and SEQ.
ID. NO. 1. The sequence of the protein encoded by the wild-type aI2 intron RNA is set forth in SEQ. ID. NO. 3.
EBSI of the a12 intron RNA comprises 6 nucleotides and is located at position 2985-2990 of the sequence set forth in SEQ. ID. NO. 1. EBSI of the wild-type a12 intron RNA has the sequence 5'-AGAAGA. The EBS2 sequence of the a12 intron RNA comprises 6 nucleotides and is located at positions 2935-2940. The EBS2 sequence of the wild-type a12 intron RNA has the sequence a12 nucleotide integrases are used to cleave substrates that have on the top strand thereof a T at positions -15 and -13 relative to the putative cleavage site, a C at position -18 relative to the putative cleavage site, and a G at position -16 or position -19 relative to the putative cleavage site. Thus, to use the a12 nucleotide integrase. one first examines the sequence of the top strand of the substrate to locate a target sequence 5'GCXXTXT or a target sequence 5'XCXGTXT, wherein X represents A, C, G, or T and wherein A represents a nucleotide having an adenine base, G represents a nucleotide having a guanine base, C represents a nucleotide have a cytosine base, and T represents a nucleotide have a thymine base. Then, if the EBS2 sequence of the aI2 intron RNA does not have substantial complementarity to the IBS2 sequence, the sequence of 6 nucleotides that lie immediately downstream from one of these target sequences, and/or if EBSI sequence of the aI2 intron RNA does not have substantial complementarity to the IBSI sequence, the sequence of six nucleotides that lie immediately downstream of the IBS2 sequence, then EBSI and EBS2 are modified to have substantial complementarity, as hereinafter explained. The efficiency of cleavage by the aI2 nucleotide integrase is increased if the top strand of the substrate has an A at -21, a G at -19, a C at -18, a G at -16, a T at -15, and a Tat -13.
The all nucleotide integrase comprises an excised, wild-type or modified excised group II intron RNA of the first intron of the S. cerevisiae mitochondrial COX1 gene, hereinafter referred to as the "all intron" RNA, and a wild-type or modified all intron-encoded protein. The sequence of the all intron RNA is shown in Fig.2 and WO 98/38337 PCT/US98/03990 SEQ. ID. NO. 2. The sequence of the protein encoded by the all intron RNA is set forth in SEQ. ID. NO. 4. The EBS1 sequence of the all intron RNA comprises 6 nucleotides and is located at position 426-431. EBSI of the wildtype all intron RNA has the sequence 5'-CGUUGA. The EBS2 sequence of the all intron RNA comprises 6 nucleotides and is located at positions 376-381. EBS2 of the wild-type all intron RNA and has the sequence
ACAAUU.
al I nucleotide integrases are used to cleave the top strand of double stranded DNA substrates that have on the top strand thereof a C at position -13 relative to the putative cleavage site. Preferably, the top strand of the substrate has a C at -13, a G at -22, a G at -21 an A at -19 and an A at -18 relative to the putative cleavage site. If the EBS2 sequence of the all intron RNA does not have substantial complementarity to the IBS2 sequence, the sequence of 6 nucleotides that lie immediately downstream from the C nucleotide at -13, and/or if EBSI sequence of the all intron RNA does not have substantial complementarity to the IBS1 sequence, the sequence of six nucleotides that lie immediately downstream of the IBS2 sequence and immediately upstream of the cleavage site, then the EBSI sequence and the EBS2 sequence of the group II intron RNA are modified to have substantial complementarity, as hereinafter explained.
The ItrA nucleotide integrase comprises an excised, wild-type or modified excised group Ll.ltrB group II intron RNA of the Lactococcus lactis ItrB gene, hereinafter referred to as the "Ll.ltrB intron" RNA, and a wild-type or modified Ll.ltrB intron-encoded protein, hereinafter referred to as the ItrA protein. The sequence of the Ll.ltrB intron RNA is shown in Fig. 10 and SEQ. ID. NO. 5. The sequence of the ItrA protein is set forth in SEQ. ID.
NO.7. The EBSI sequence of the Ll.ltrB intron RNA comprises 7 nucleotides and is located at positions 457 to 463.
The EBS1 sequence of the wild-type Ll.ltrB intron RNA has the sequence 5'-GUUGUGG. The EBS2 of the Ll.ltrB intron RNA comprises 6 nucleotides and is located at positions 401 to and including 406. The EBS2 sequence of the wild-type Ll.ltrB intron RNA has the Sequence 5'AUGUGU. The ItrA nucleotide integrase is used to cleave the top strand of a double-stranded DNA substrate when the top strand has a G at -21 and an A at -20 relative to the cleavage site. The ItrA nucleotide integrase cuts the top strand more efficiently when there is a G at -21, an A at -20, a T at -19, a Gat-17, and a Another method uses a nucleotide integrase for cleaving both strands of double-stranded DNA and for attaching the group II intron RNA molecule into the cleavage site of the top strand of the DNA substrate. The nucleotide integrase comprises a group II intron-encoded protein bound to an excised group II intron RNA, wherein the group II intron RNA has an EBSI sequence and an EBS2 sequence that have substantial complementarity to the IBSI sequence and IBS2 sequence, respectively, on the top strand of the substrate. The EBSI sequence comprises from about 5 to 7 nucleotides. The EBS2 sequence comprises from about 4 to 7 nucleotides. If the nucleotides of EBS1 and EBS2 of the group II intron RNA are not at least 80% complementary to the nucleotides of IBSI and IBS2, the non-complementary nucleotides are modified, preferably, by recombinant techniques. Preferably, the 8 nucleotide of the group II intron RNA is complementary to the nucleotide at +1 in the top strand. If the 6 nucleotide is not complementary to the nucleotide at preferably the 6 nucleotide is modified to be complementary. The group II intron-encoded protein comprises an RT domain, an X domain, and the conserved and non-conserved regions of a Zn WO 98/38337 PCT/US98/03990 domain. To insert a cDNA into the cleavage site on the bottom strand of the substrate, the group II intron-encoded protein also comprises a reverse transcriptase domain.
The method of cleaving both strands of a double-stranded DNA sequence having a recognition site comprises the steps of: providing a nucleotide integrase comprising a group II intron RNA having two sequences, EBS 1 and EBS2, that are capable of hybridizing with two intron RNA-binding sequences, IBS 1 and IBS2, on the top strand of the DNA substrate, and a group II-intron encoded protein that binds to a first sequence element and to a second sequence element in the recognition site of the substrate; and reacting the nucleotide integrase with the doublestranded DNA substrate for a time and at a temperature sufficient to permit the nucleotide integrase to cleave both strands of the DNA substrate and to insert the group II intron RNA into the cleavage site of the top strand. The first sequence element of the recognition site is upstream of the putative cleavage site, the IBSI sequence and the IBS2 sequence. The first sequence element comprises from about 10 to about 12 pairs of nucleotides. The second sequence element comprises from about 10 to about 12 nucleotides and lies downstream of the cleavage site, from position +1 to about position +10, +11, or +12.
Nucleotide integrases that may be employed to cleave both strands of a DNA substrate include, but are not limited to an aI2 nucleotide integrase, an all nucleotide integrase, and an ItrA nucleotide integrase. The preferred recognition site for the a12 nucleotide integrase comprises on the top strand thereof a C at -18, a T at -15, a T at -13, a G at -16 or -19, a T at a T at and a G at +6 relative to the cleavage site. To use the a12 nucleotide integrase to cleave both strands of the DNA substrate, one first examines the substrate sequence to determine if one strand thereof contains this set of nucleotides. Then, if the EBS2 sequence of the a12 intron RNA does not have substantial complementarity to the IBS2 sequence of the substrate, the sequence of 6 nucleotides that lies immediately downstream from the T at -13, and/or if EBSI sequence of the a12 intron RNA does not have substantial complementarity to the IBSI sequence, the sequence of six nucleotides that lie immediately downstream of the IBS2 sequence and immediately upstream of the T at then the EBSI sequence and EBS2 sequence of the group II intron RNA are modified to have substantial complementarity, as hereinafter explained. The aI2 nucleotide integrase cleaves both strands of the substrate with greater efficiency if the top strand of the substrate has an A at -21, a G at -19, a C at -18, a G at -16, aT at -15, aT at -13, aT at a T at and a G at The aI2 cleaves both strands of the substrate with even greater efficiency if the top strand has an A at -21, a T at -20, a G at -19, a C at -18, -a T at -17, a G at -16, a T at -15, a T at -13 a T at a T at and a G at If the top strand of the substrate additionally has a C at a T at a T at an A at an A at and a T at +10, cleavage will be even greater.
The all integrase is used to cleave both strands of a DNA substrate that has on the top strand thereof aC residue at position -13 relative to the cleavage site a T at aT at a T at aT at an A at a G at a T at and an A at +8 relative to the cleavage site. Preferably, the top strand of the double-stranded substrate has a C at -13, a G at -22, a G at-21, an A at -19 aT at a T at+2, a Tat a Tat+4, an A at a G at aT at and an A at Cleavage is more efficient if there is a G at -22, a G at -21, an A at -19, an A at 18, a C at -13, a T at +1, an T at an T at aT at aA at a G at aT at an A at aG at and aT at 10 on the top strand of the DNA substrate. If the top strand of the substrate additionally comprises a T at -20, a T at -17, a T at -16, a C at and an A at -14, cleavage will be even greater.
WO 98/38337 PCT/US98/03990 The ItrA nucleotide integrase is used to cleave both strands of a double-stranded DNA substrate.
when the substrate has on the top strand thereof a G at -21, an A at -20 a C an A at a T at an A at a T at a C at an A at and a T at The ItrA nucleotide integrase cleaves both strands of the substrate more efficiently if the top strand has a G at -21, an A at -20, a T at -19, a G at-17, and G at -15, a C an A at a T at an A at a T at a C at an A at and a T at If the top strand additionally has a C at -22, a C at -18. a T at -16, an A at -14, an A at -13, a T at +9 and a T at +10, cleavage will be even greater.
Another method uses a nucleotide integrase for cleaving a single-stranded nucleic acid substrate, i.e., a single-stranded DNA or RNA, and for attaching the group II intron RNA molecule into the cleavage site. The method comprises the steps: providing a nucleotide integrase comprising: a group II intron RNA having two hybridizing sequences, EBSI and EBS2, which are capable of hybridizing with two intron RNA-binding sequences, IBSI and IBS2, respectively on the substrate, and a group II intron encoded protein having an RT domain, an X domain and the non-conserved portions of the Zn domain; and reacting the substrate with the nucleotide integrase. The EBS1 sequence of the group II intron RNA comprises from about 5 to 7 nucleotides and has at least 80%, preferably and more preferably full complementarity with the nucleotides at positions -1 to about -5 or about The EBS2 sequence of the group II intron RNA comprises 4 to 7 nucleotides and has at least 80%, preferably 90%, more preferably full complementarity with the nucleotides at positions from about -6 to about -14. Preferably, the nucleotide immediately preceding the first nucleotide of EBS 1 is complementary to the nucleotide at +1 in the sense strand.
The present invention also provides a method of determining whether a nucleic acid substrate comprises a particular recognition site. The method comprises the steps of providing a nucleotide integrase capable of cleaving a nucleic acid substrate with a particular recognition site; reacting the nucleotide integrase with the nucleic acid substrate; and assaying for cleavage of the substrate. Cleavage of the substrate indicates that the substrate comprises the particular recognition site. In addition to assaying for fragmentation and alterations in size of the nucleic acid substrate, cleavage may be detected by assaying for incorporation into or attachment of the group II intron RNA to one strand of the nucleic acid substrate.
While a wide range of temperatures are suitable for the methods herein, good results are obtained at a reaction temperature of from about 30 0 C to about 42 0 C, preferably from about 30° to about 37 0 C. A suitable reaction medium contains a monovalent cations such as Na' or at a concentration from about 0 to about 300 mM: preferably from about 10 to about 200 mM KCI, and a divalent cation, preferably a magnesium or manganese ion, more preferably a magnesium ion, at a concentration that is less than 100 mM and greater than 1 mM. Preferably the divalent cation is at a concentration of about 5 to about 20mM, more preferably about 10 to about 20 mM. The preferred pH for the medium is from about 6.0-8.5, more preferably about 7.5-8.0.
In the above-described methods it is believed that the single stranded nucleic acid substrates and the top strand of the double-stranded DNA substrate are cut by the excised group II intron RNA. The cleavage that is catalyzed by the excised group II intron RNA is a reverse splicing reaction that results in the insertion, either partially or completely, of the excised group II intron RNA into the cleavage site, i.e. between nucleotides -1 and in the top strand. During partial insertion the group II intron RNA is covalently attached to the +1 nucleotide on the top strand WO 98/38337 PCT/US98/03990 of the cleavage site. It is believed that the bottom strand or antisense strand of the double-stranded DNA substrate is cut by the group II intron-encoded protein. The bottom strand of the double-stranded DNA substrate is cut at a position from about 9 to about 11 base pairs downstream of the cleavage site in the top strand, at a site between nucleotide positions +10, and +11.
The methods of using a nucleotide integrase as an endonuclease to cleave a substrate DNA are useful analytical tools for determining the presence and location of a particular recognition site in a DNA substrate.
Moreover, the simultaneous insertion of a nucleic acid molecule into the DNA substrate, which occurs when either single-stranded DNA or double-stranded DNA is cleaved with a nucleotide integrase, permits tagging of the cleavage site of the DNA substrate with a radiolabeled molecule, a feature which facilitates in identifying DNA substrates that contain a particular recognition site. In addition, the automatic attachment of an RNA molecule onto one strand of a double-stranded DNA substrate permits identification of the cleavage site through hybridization studies that use a probe that is complementary to the attached RNA molecule. An attached RNA molecule that is tagged with a molecule such as biotin also enables the cleaved strand to be affinity purified.
The methods of using nucleotide integrases to cleave RNA and DNA substrates having a recognition site are useful for rendering certain genes within the substrates nonfunctional. Such methods are also useful for inserting a nucleic acid into the cleavage site, thus, changing the characteristics of the RNA molecules and the protein molecules encoded by the substrates.
The nucleotide integrase The nucleotide integrase is a ribonucleoprotein ("RNP) particle and comprises a group II intron encoded RNA and a group II intron encoded protein, which protein is bound to the RNA. Preferably, the group II intron RNA is an excised group II intron RNA. "Excised group II intron RNA," as used herein, refers to an RNA that is either an in vitro or in vivo transcript of the DNA of the group II intron and that lacks flanking exon sequences. The excised group II intron RNA is obtained from wild type organisms, or mutated organisms, by in vivo transcription and splicing, or by in vitro transcription and splicing from the transcript of a modified or unmodified group II intron.
"Group II intron encoded protein" as used herein, is a protein encoded by a group II intron open reading frame.
Group II introns are a specific type of intron which is present in the DNA of bacteria and in the DNA of organelles, particularly the mitochondria of fungi, yeast and plants and the chloroplast of plants. The group II intron RNA molecules, that is, the RNA molecules which are encoded by the group II introns, share a similar secondary and tertiary structure. Figure 2 depicts the secondary structure of the all and a12 intron RNA and part of the nucleotide sequence of the wild-type all and aI2 intron RNA. The group II intron RNA molecules typically have six domains. Domain IV of the group II intron RNA contains the nucleotide sequence which encodes the "group II intron encoded protein." Nucleotide integrases include, for example, excised group II intron RNA molecules having a sequence which is identical to a group II intron RNA that is found in nature, i.e. a wild-type group II intron RNA, and excised group II intron RNA's which have a sequence different from a group II intron RNA that is found in nature, i.e.
a modified, excised group II intron RNA molecule. Modified excised group II intron RNA molecules, include, for WO 98/38337 PCT/US98/03990 example, group 11 intron RNA molecules that have nucleotide base changes or additional nucleotides in the internal loop regions of the group II intron RNA, preferably the internal loop region of domain IV and group II intron RNA molecules that have nucleotide base changes in the hybridizing regions of domain I. Nucleotide integrases in which the group II intron RNA has nucleotide base changes in the hybridizing region, as compared to the wild type, typically have altered specificity for the substrate DNA of the nucleotide integrase.
The group II intron-encoded protein of the nucleotide integrase comprises an X domain and a Zn domain. The X domain of the protein has a maturase activity. The Zn domain of the protein has Zn 2 finger-like motifs. Preferably, the group II intron-encoded protein further comprises a reverse transcriptase domain. As used herein, a group II intron-encoded protein includes modified group II intron-encoded proteins that have additional amino acids at the N terminus, or C terminus, or alterations in the internal regions of the protein as well as wild-type group II intron-encoded proteins. It is believed that the group II intron-encoded protein is bound to 3' region of the group II intron RNA.
The nucleotide integrase are provided in the form of RNP particles isolated from wild-type, mutant, or genetically-engineered organisms. The nucleotide integrase are also provided in the form of reconstituted RNP particles isolated from a reconstituted RNP particle preparation. The nucleotide integrase also comprises reconstituted RNP particles that are formed by combining an exogenous synthetic, excised group II intron RNA with either a group II intron-encoded protein or an RNA-protein complex preparation. The exogenous RNA includes both unmodified and modified group II intron RNA molecules. Preferably, the exogenous RNA is an in vitro transcript or a derivative of an in vitro transcript of an unmodified or modified group II intron. For example, the exogenous RNA may be derived by splicing from an in vitro transcript. The RNA-protein complex preparation contains group II intronencoded protein molecules complexed to RNA molecules that are not an excised group II RNA molecule having a sequence which encodes this protein. The group II intron-encoded protein of the RNA-protein complex is associated with either a ribosomal RNA molecule, an mRNA molecule, or an excised group II intron RNA that does not encode the group ll-intron encoded protein.
The nucleotide integrase may be used as a purified RNP particle or a purified reconstituted particle.
Alternatively, the nucleotide integrase may be used in a partially-purified preparation which contains the RNP particles and reconstituted particles that have nucleotide integrase activity as well as other RNP particles, such as for example ribosomes. This partially-purified preparation is free of organelles.
Preparation of the Nucleotide Integrase The nucleotide integrase is isolated from wild type or mutant yeast mitochondria, fungal mitochondria, plant mitochondria, chloroplasts, the proteotobacterium Azotobacter vinelandii, the cyanobacterium Calothrix, and Escherichia coli lactococcus lactis. The procedure for isolating the RNP particle preparation involves mechanically and/or enzymatically disrupting the cell membranes and/or cell walls of the organisms. In the case of fungi and plants, the purification also involves separating the specific organelles, such as mitochondria or chloroplasts, from the other cellular components by differential centrifugation and/or flotation gradients and then lysing the organelles with a nonionic detergent, such as Nonidet P-40. The organelle and bacterium lysates are then centrifuged WO 98/38337 PCT/US98/03990 through a sucrose cushion to obtain the ribonucleoprotein (RNP) particle preparation. The RNP particles may be further purified by separation on a sucrose gradient, or a gel filtration column, or by other types of chromatography.
The nucleotide integrase is also isolated from reconstituted RNP particle preparations that are prepared by combining an RNA-protein complex preparation with an exogenous, excised group II intron RNA. The RNA-protein complex preparation is preferably isolated from a yeast, fungi, or bacterium using the protocol for RNP panicles described above. The RNA-protein complex preparation comprises group II intron-encoded protein molecules complexed with RNA molecules that are not an excised group II intron RNA having a sequence that encodes the group II intron-encoded protein. The group II intron-encoded protein of the RNA-protein complex preparation is associated with either a ribosomal RNA molecule, an mRNA molecule, or an excised group II intron RNA that does not encode the group II-intron encoded protein.
The exogenous RNA preferably is a synthetic molecule made by in vitro transcription or by in vitro transcription and self-splicing of the group II intron. The exogenous RNA may also be made by isolation of the group II intron RNA from cells or organelles in which it is naturally present or from cells in which an altered intron has been inserted and expressed. The exogenous RNA is then added to a preparation containing the RNA-protein complex.
Preferably, the exogenous group II intron RNA is first denatured. The exogenous RNA is added to the RNA-protein complex on ice.
In another embodiment, the nucleotide integrase is made by introducing an isolated DNA molecule which comprises a group 11 intron DNA sequence into a host cell. Suitable DNA molecules include, for example, viral vectors, plasmids, and linear DNA molecules. Following introduction of the DNA molecule into the host cell, the group II intron DNA sequence is expressed in the host cell such that excised RNA molecules encoded by the introduced group II intron DNA sequence and protein molecules encoded by introduced group II intron DNA sequence are formed in the cell. The excised group II intron RNA and group II intron-encoded protein are combined within the host cell to produce the nucleotide integrase.
Preferably the introduced DNA molecule also comprises a promoter, more preferably an inducible promoter, operably linked to the group II intron DNA sequence. Preferably, the DNA molecule further comprises a sequence which encodes a tag to facilitate isolation of the nucleotide integrase such as, for example, an affinity tag and/or an epitope tag. Preferably, the tag sequences are at the 5' or 3' end of the open reading frame sequence. Suitable tag sequences include, for example, sequences which encode a series of histidine residues, the Herpes simplex glycoprotein D, the HSV antigen, or glutathione S-transferase. Typically, the DNA molecule also comprises nucleotide sequences that encode a replication origin and a selectable marker. Optionally, the DNA molecule comprises sequences that encode molecules that modulate expression, such as for example T7 lysozyme.
The DNA molecule comprising the group II intron sequence is introduced into the host cell by conventional methods, such as, by cloning the DNA molecule into a vector and by introducing the vector into the host cell by conventional methods, such as electroporation or by CaCl 2 -mediated transformation procedures. The method used to introduce the DNA molecule is related to the particular host cell used. Suitable host cells are those which are capable of expressing the group II intron DNA sequence. Suitable host cells include, for example, heterologous or homologous bacterial cells, yeast cells, mammalian cells, and plant cells. In those instances where the host cell genome WO 98/38337 PCT/US98/03990 and the group II intron DNA sequence use different genetic codes, it is preferred that the group II intron DNA sequence be modified to comprise codons that correspond to the genetic code of the host cell. The group II intron DNA sequence, typically, is constructed de novo from synthetic oligonucleotides or modified by in vitro site-directed mutagenesis to prepare a group II intron DNA sequence with different codons. Alternatively, to resolve the differences in the genetic code of the intron and the host cell, DNA sequences that encode the tRNA molecules which correspond to the genetic code of the group II intron are introduced into the host cell. Optionally, DNA molecules which comprise sequences that encode factors that assist in RNA or protein folding, or that inhibit RNA or protein degradation are also introduced into the cell.
The DNA sequences of the introduced DNA molecules are then expressed in the host cell to provide a transformed host cell. As used herein the term "transformed cell" means a host cell that has been genetically engineered to contain additional DNA, and is not limited to cells which are cancerous. Then the RNP particles having nucleotide integrase activity are isolated from the transformed host cells.
Preferably, the nucleotide integrase is isolated by lysing the transformed cells, such as by mechanically and/or enzymatically disrupting the cell membranes of the transformed cell. Then the cell lysate is fractionated into an insoluble fraction and soluble fraction. Preferably, an RNP particle preparation is isolated from the soluble fraction. RNP particle preparations include the RNP particles having nucleotide integrase activity as well as ribosomes, mRNA and tRNA molecules and other RNPs. Suitable methods for isolating RNP particle preparations include, for example, centrifugation of the soluble fraction through a sucrose cushion. The RNP particles, preferably, are further purified from the RNP particle preparation or from the soluble fraction by, for example, separation on a sucrose gradient, or a gel filtration column, or by other types of chromatography. For example, in those instances where the protein component of the desired RNP particle has been engineered to include a tag such as a series of histidine residues, the RNP particle may be further purified from the RNP particle preparation by affinity chromatography on a matrix which recognizes and binds to the tag. For example, NiNTA Superflow from Qiagen, Chatsworth CA, is suitable for isolating RNP particles in which the group II intron-encoded protein has a His 6 tag.
The following methods for preparing nucleotide integrases are included for purposes of illustration and are not intended to limit the scope of the invention.
FORMULATIONS
The RNP particle preparations of the following formulations 1-10, and the RNA-protein complex of the formulation 12 were isolated from the mitochondria of the wild-type Saccharomyces cerevisiae yeast strain ID41-6/161 MATa adel lysl, hereinafter designated "161", and derivatives thereof. The mitochondria of the wild-type yeast strain 161 contains a COXI gene that includes the group II intron all and the group II intron aI2.
The COX1 gene in the mutant yeast strains either lacks one of the group II introns or has a mutation in one of the group II introns. The excised group II intron RNA molecules and the group II intron encoded proteins are derived from the group II introns all and a12 that are present in the wild-type and mutant yeast strains.
WO 98/38337 PCT/US98/03990 The intron composition of the COXI gene in the different yeast strains is denoted by a convention in which a superscript indicates the presence of the all intron or the aI2 intron, a superscript indicates the absence of the al or al2 intron, and other superscripts refer to specific alleles or mutations in the a12 intron.
Formulation I An RNP particle preparation was isolated from the mitochondria of the Saccharomyces cerevisiae wild-type yeast strain 161. The intron composition of the COX] gene of the wild-type strain is The RNP particle preparation contains an RNP particle that is derived from the all intron and includes an excised all RNA bound to a protein encoded by all. The preparation also contains an RNP particle that is derived from the a12 intron and that comprises a excised al2 RNA molecule and an associated al2-encoded protein.
To prepare the RNP particle preparation, the yeast were inoculated into a 1 liter liquid culture medium containing 2% raffinose, 2% BactoPeptone from Difco and 1% yeast extract from Difco to an O.D.
59 5 of 1.6- 1.7. The cell walls were digested with 40 mg of the yeast lytic enzyme from ICN, and the cells broken by mechanical disruption with glass beads. The nuclei and cell debris were pelleted from the lysate by centrifugation for 5 minutes in a Beckman GSA rotor at 5,000 rpm. The superatant was removed and centrifuged in a Beckman GSA rotor at 13,000 rpm for 15 minutes to obtain a mitochondrial pellet. The mitochondria were layered on a flotation gradient consisting of a 44% sucrose solution layer, a 53% sucrose solution layer, and a 65% sucrose solution layer and centrifuged in a Beckman SW28 rotor at 27,000 rpm for 2 hours and 10 minutes. The mitochondria were collected from the 53%/44% interface and suspended in buffer containing 0.5M KCI, 50 mM CaCI, 25 mM Tris-HC1, pH 7.5, 5 mM DTT and lysed by the addition ofNonidet P-40 to a final concentration of The mitochondrial lysate was then centrifuged in a Beckman 50Ti rotor at 50,000 rpm for 17 hours through a 1.85 M sucrose cushion in a buffer containing 0.5M KCI, mM CaCI,, 25 mM Tris-HC1, pH 7.5, 5 mM DTT, to obtain a pellet of RNP particles that were largely free of mitochondrial proteins. The isolated RNP particles were resuspended in 10 mM Tris-HCI, pH 8.0 and 1 mM DTT and stored at -70 0 C. The preparation may be repeatedly thawed and frozen before use.
Formulation la Purified RNP particle 2.5 O.D.
2 60 of the RNP particles from formulation 1 in a volume of 150 pl were layered onto a 12 ml 5-20% linear sucrose gradient in a buffer consisting of 100 mM KCI, 2 mM MgCl1, 50 mM Tris-HCI, pH 7.5, and mM DTT. The gradient was centrifuged in an SW41 rotor at 4 0 C at 40,000 rpm for five hours. The gradient was fractionated into 35 fractions of approximately 0.325 ml. Fractions 12-20 contain the purified RNP particles which are substantially free of ribosomal RNA. The location of the RNP particles in the gradient fractions was independently verified by Northern hybridization with aI2 antisense RNA. The location of the small and large subunits of ribosomal RNA in the gradient fractions was independently verified by ethidium bromide staining of the fractions on a 1% agarose gel. Approximately 85% of the ribosomal RNA is found in a fraction that does not contain the RNP particles which comprise the nucleotide integrase.
Formulation 2 RNP particle preparation from mutant yeast strain 1°2*' The RNP particles comprise an excised aI2 RNA and an aI2-encoded protein. Yeast strain 1T'' was obtained from Dr. Philip S. Perlman at the University of Texas Southwestern Medical Center and was prepared as WO 98/38337 PCT/US98/03990 described in Moran et al., 1995, Mobile Group II Introns of Yeast Mitochondrial DNA Are Novel Site-Specific Retroelements, Mol. Cell Biol. 15, 2828-38, which is incorporated herein by reference. The 102' mutant strain was constructed as follows: the a12 intron from strain 161 was cloned as a Clal-to-BamHl fragment into pBluescript KS* obtained from Stratagene to yield pJVM4; (ii) pJVM4 was cleaved with Clal and Ndel to remove the 5' end of the insert; and (iii) an Mspl-to-Ndel fragment that contains exons 1 and 2 of the mitochondriae COX] gene plus the 5' end of al2 from yeast strain C10361Aone was inserted to yield plasmid pJVM164. Yeast strain C10361Aone, in which all is excised from the mitochondrial DNA, was prepared as described in Kennell et al., 1993, Reverse transcriptase activity associated with maturase-encoding group II introns in yeast mitochondria. Cell 73, 133-146, which is incorporated herein by reference. pJVM164 was transformed into a [rho°] strain, and the 1°2' allele was placed into an intact mitochondrial DNA by recombination. This last step is accomplished by mating to a nonreverting COXI mutant derived from mutant C1036 (strain 5B), whose construction is described in Kennel et al., 1993, and selecting for recombinant progeny that are capable of respiring and growing on glycerol-containing medium (GLY) and that contain the transformed COXI allele in place of the 5B allele.
The reactions and manipulations directed at cloning DNA, such as ligations, restriction enzyme digestions, bacterial transformation, DNA sequencing etc. were carried out according to standard techniques, such as those described by Sambrook et al., Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press.
Cold Spring Harbor. N.Y. Yeast mitochondrial transformations were also carried out according to standard techniques such as those described in Belcher et al., 1994, Biolistic transformation of mitochondria in Saccharomyces cerevisiae, 101-115. In Yang and P. Christou Particle Bombardment Technology for Gene Transfer. Oxford University Press, New York. The RNP particle preparation was made from the mitochondria of mutant yeast strain 1o2', as in formulation 1.
Formulation 3 RNP particle preparation from mutant yeast strain 1'20 Yeast strain 1"'2 is a derivative of the wild-type yeast strain 161. The yeast strain "'2 0 was obtained from Dr. Philip S. Perlman and was prepared as described in Kennell et al., 1993. Cell 73, 133-146. Yeast strain 1"'2 contains a segment of the COXI gene of S. diastaticus, which lacks a12, inserted into wild-type 161 mtDNA via mitochondrial transformation. The construction started with plasmid pSH2, which contains all from wildtype 161 and some flanking sequences cloned as a Hpall/EcoRl fragment in pBS(+) (Stratagene, La Jolla, CA). That plasmid was cleaved near the 3' end of all with Clal and in the downstream polylinker with BamHI, and the gap was filled with a Clal/BamHl fragment from S. diastaticus mitochondrial DNA (NRRL Y-2416) that contains the 3' end of all, E2, E3 and most of aI3, thus creating a 1"2° form of the COXI gene. The plasmid containing the hybrid COX1- 1 '2 segment was transformed into a rho° derivative of strain MCC109 (MATa ade2-101 ura3-52 kar by biolistic transformation. The resulting artificial petite was crossed to strain n161/m161-5B, and gly* recombinants containing the COXI 11"2 allele in the n161 background were isolated. The hybrid all allele, which is spliced normally, differs from that of wild-type 161 by one nucleotide change, C to T, at position 2401, changing Thr7 44 to Leu in the intron open reading frame. The RNP particle preparation was made from the mitochondria of mutant yeast strain 1"2° as in formulation 1. The RNP particles comprise an excised all RNA molecule and an all encoded protein.
Formulation 4 RNP particle preparation from mutant yeast strain 10 2 YA H H WO 98/38337 PCT/US98/03990 Yeast strain 1 0 2 was obtained from Dr. Philip S. Perlman and was made as described in Moran et al., 1995, Mol. Cell Biol. 15, 2838-38., using a mutagenized pJVM164 plasmid. The allele was made by oligonucleotide-directed mutagenesis of pJVM 164 which contains a 4.4 kb MspI/BamHI fragment extending from 217 nucleotides upstream of exon I through intron a13 of the COX1 allele. The mutagenesis changes the aI2 nucleotides 1473 to 1478 from GAT GAT to CAT CAT (D-491D-492 to HH). The RNP particles comprise a mutated, excised a12 RNA and an al2-encoded protein that has the mutation YADDYAHH in the reverse transcriptase domain of the protein. The RNP particle preparation was made from the mitochondria of mutant yeast strain 1
I
2 YAHH as in formulation 1.
Formulation 5 RNP particles from the mutant yeast strain 102" 4T The mutant yeast strain 10 2 P'4T was obtained from Dr. Philip S. Perlman and was constructed according to the procedure described in Kennell et al., 1993, Cell 73, 133-146, where it is named n161/m161- C1036A1. The RNP particles comprise a mutated, excised aI2 intron RNA molecule and an aI2-encoded protein that carries the missense mutation P 7 1 4 T in the Zn domain. The RNP particle preparation was made from mitochondria of mutant yeast strain 10 2 P714T as in formulation 1.
Formulation 6 RNP particle from mutant yeast strain 12HH" The mutant yeast strain 1 o 2 mVR w was obtained from Dr. Philip S. Perlman and was made by using the nucleotide described in Moran et al., 1995, Mol. Cell Biol. 15, 2828-38, which is incorporated herein by reference, using a mutagenized pJVM164 plasmid. The allele was constructed by site-directed mutagenesis of pJVM164. The a12 intron has the following changes: positions 2208-2219 from CATCACGTAAGA SEQ. ID. NO. 9 to GCAGCTGCAGCT,
(H,
73
H,
37
V
73
,R
73 to AAAA) and A 2 227 A to T (N 7
,J
4 This nucleotide integrase preparation comprises a mutated, excised aI2 intron RNA and an al2-encoded protein that has a missense mutation in the HHVR motif. The RNP particle preparation was made from mitochondria of mutant yeast strain 1 0 2 IV
R
Formulation 7 RNP particle from mutant yeast strain 10 2 2 ConZ The mutant yeast strain 1 2 c o zn was obtained from Dr. Philip S. Perlman and was made as described in Moran et al., 1995, Mol. Cell Biol. 15, 2828-38, using a mutagenized pJVM164 plasmid. The allele was constructed by oligonucleotide-directed mutagenesis of pJVM164. The aI2 intron has the following changes:positions 2157-2165 changed from TTATTTAGT to TAATAATAA
(L
719
F
2 0
S
72 1 to OchOchOch). RNP particles comprise a mutated, excised a12 intron RNA and an al2-encoded protein that lacks the most conserved motifs in the Zn domain.
The RNP particle preparation was made from mitochondria of mutant yeast strain 1o 2
A
co"z".
Formulation 8 RNP particle from mutant east strain 1 2
CC/C
The mutant yeast strain 1 2 c-c" was obtained from Dr. Phillip S. Perlman and was made by using a nucleotide described in Moran et al., 1995 Mol. Cell Biol. 15, 2828-38, using a mutagenized pJVMI64 plasmid. The allele was constructed by site-directed mutagenesis of pJVM164. The a12 intron has the following changes:positions 2172-2173 changed from TG to GC (C, 24 A) and 2180-2182 changed from TTG to AGC (1 726
C
727 to MA). The RNP particles comprise a mutated, excised a12 intron RNA and an al2-encoded protein that has three amino acid residues changed in the first Zn"-finger-like motif. The RNP particle preparation was made from mitochondria of mutant yeast strain 102 c-c' WO 98/38337 PCT/US98/03990 Formulation 9 RNP particles from mutant yeast strain 1 0 2 c-C n The mutant yeast strain l" 2
C
c 2 was obtained from Dr. Philip S. Perlman and was made as described in Moran et al., 1995 Mol. Cell Biol. 15,2828-38, using a mutagenized pJVMI64 plasmid. The allele was constructed by site-directed mutagenesis of pJVM164. The aI2 intron has the following changes: position 2304-2305 changed from TG to GC (C 7 68 A) and 2313-2314 changed from TG to GC (C 77 The RNP particles comprise a mutated excised aI2 intron RNA and an al2-encoded protein that has two amino acids changed in the second Zn" 2 finger-like motif. The RNP particle preparation was made from mitochondria of mutant yeast strain 1 2 c .c 2 Formulation 10 RNP particles from mutant yeast strain 1c 2 H6 The mutant yeast strain, obtained from Dr. Philip S. Perlman, was made by transferring the mutagenized plasmid pJVM164 into the mitochondria of yeast strain GRF18 as described in Moran et al., 1995 Ref.
The allele was constructed by site-directed mutagenesis of pJVM164 and has the sequence CATCATCATCATCATCAT, SEQ. ID. NO. 10, inserted between nucleotides 2357 and 2358 of the aI2 intron. The RNP particle preparation was made from mitochondria of mutant yeast strain 1°2" 6 according to the protocol described above for formulation 1. The RNP particles comprise a mutated, excised aI2 intron RNA and an aI2-encoded protein that has six histidines added to the C terminus of the aI2-encoded protein.
Formulation 11 RNP particles from Neurospora intermedia.
Mitochondria from the Varkud strain of Neurospora intermedia, which is available from the Fungal Genetics Stock Center, were prepared as described in Lambowitz A.M. 1979, Preparation and analysis of mitochondrial ribosomes. Meth. Enzymol. 59, 421-433. The conidia were disrupted with glass beads and the mitochondria and RNP particles isolated as described in formulation 1. The RNP particles comprise an excised col intron RNA and the protein encoded by the col intron.
Formulation 12 Reconstituted RNP particle preparation A reconstituted RNP particle preparation was made by incubating an exogenous, excised, in vitro RNA transcript of the a12 intron with an RNA-protein complex preparation isolated from the mutant yeast strain 1 0 2
A
DS
in which the aI2 intron RNA lacks a domain V and is therefore splicing defective. The mutant allele 1°2 D5 was obtained from Dr. Philip S. Perlman and was constructed using the same procedure that was used to make yeast strain 1'2dS that was described in Moran et al. 1995, except that the final mating was with yeast strain 1 0 2. The RNAprotein complex preparation was isolated from 1 °2 aD 5 using the protocol described above in formulation 1 for RNP particle preparations The RNA-protein complex preparation isolated from the mitochondria of 1 2 6 DS does not contain excised aI2 RNA but does contain al2-encoded protein that is associated with other RNA molecules in the preparation.
The exogenous RNA was made by in vitro transcription of the plasmid pJVM4 which includes a fragment of the yeast mitochondrial COX1 gene from the Clal site of the group II intron 1 (all) to the BamHI site of a13 that has been inserted into the pBLUESCRIPT plasmid. Plasmid pJVM4 contains the following COXI sequences: Exon 2, a12, Exon 3 and parts of all and a13 sequence. The sequences are operably linked to a T3 RNA polymerase promoter. The Exon 2 and Exon 3 sequence are required for self-splicing of the aI2 intron RNA from the WO 98/38337 PCT/US98/03990 RNA transcript. pJVM4 was linearized with BslEll, which cuts at the 3' end of Exon 3 then 5 pg of the plasmid was incubated in 0.300 ml of 40 mM Tris-HCI at pH 8.0, 25 mM NaC1, 8 mM MgCL 2 2 mM spermidine, 5 mM DTT 500 mM rNTPs, 600 U of RNasin from US Biochemical and 300-750 U of T3 RNA polymerase from BRL at 37 0 C for 2 hours to make the RNA transcripts. Following the incubation, the RNA transcripts were phenol-CIA extracted, purified on G-50 column, phenol-CIA extracted and precipitated with ethanol. The RNA transcripts were then incubated in 40 mM Tris-HCl at pH 7.5, 100 mM MgC 2 2 M NH 4 CI at 40-45 0 C for 1 hour to allow self-splicing of the a12 intron RNA molecules from the RNA transcripts and to obtain the splicing products. The splicing products, which include the excised aI2 RNA transcript, the ligated transcript which lacks the aI2 intron RNA, and the unspliced transcript, were desalted by passing through a G-50 column, then phenol-CIA extracted and ethanol precipitated to provide the exogenous RNA. The exogenous RNA was then resuspended to a final concentration of 1.0 pg/pl in mM Tris-HCI, pH 8.0, 1 mM EDTA.
To prepare the reconstituted RNP particle preparation, 1 ul of the exogenous RNA was added to 2 pl of the 1 o 2
A
D S RNA-protein complex preparation (0.025 O.D.
260 units) on ice for 0-10 minutes. The preparation was used immediately.
Formulation 13 Reconstituted RNP Particle Preparation containing a Nucleotide Integrase Comprisino a Group II Intron RNA Having Modified EBS Sequences Plasmid pJVM4 derivatives were used to prepare exogenous aI2 intron RNA molecules in which the EBSI and EBS2 sequences are different from the EBS sequences in the wild-type a12 intron. pJVM4 contains the a12 intron sequence and flanking exon sequences from wild-type yeast 161 cloned downstream of a phage T3 promoter in pBluescript II Plasmids containing modified introns were derived from pJVM4 by PCR mutagenesis with appropriate primers. In all cases, the modified region was sequenced to verify the correct mutation and the absence of adventitious mutations.
Plasmids pJVM4-alIEBS1, pJVM4-allEBS2 and pJVM4-allEBSI/EBS2 contain a12 RNA derivatives in which the EBS1 and/or EBS2 sequences were replaced with those of all. In each case, portions of the and 3' exons were also changed to all sequences to permit in vitro splicing. pJVM4-aIlEBSI has EBSI positions 2985-2990 changed from 5'AGAAGA to 5'CGTTGA; pJVM4-allEBS2 has EBS2 positions 2935-2940 changed from TCATTA to 5' ACAATT; and pJVM4-allEBS1EBS2 has EBSI and EBS2 positions 2935-2940 and 2985-2990 changed from 5' TCATTA to 5' ACAATT and 5' AGAAGA to 5' CGTTGA, respectively. For pJVM4-a IEBSI and pJVM4-allEBSl/EBS2, the 5' portion of the pJVM4 insert consisting of all and E2 sequence was replaced with the last 24 bp of El. For pJVM4-aIlEBS2, positions -24 to -7 (GTCATGCTGTATTAATGA) SEQ. ID. NO. 11 were replaced with (ATGGTAATTCACAATTAT), SEQ. ID. NO. 12 leaving the aI2 IBSI sequence unchanged. For all three constructs, the 3' portion of the insert was replaced by the first 15 bp of E2 instead of E3 and aI3.
pJVM4-EBS2-8G, pJVM4-EBS2-9T-10A, pJVM4-EBS2-11A, pJVM4-EBS2-12T, and pJVM4- EBS2-13T(1) are derivatives of pJVM4 in which the indicated changes were introduced at different positions in EBS2.
pJVM4-EBS2-13T(2) is identical to pJVM4-EBS2-13T(l) except that it contains a second mutation, T to A, at intron position 2932.
WO 98/38337 PCT/US98/03990 pJVM4-8-C, pJVM4-5-G, and pJVM9-5-T are derivatives of pJVM4 in which the 8 nucleotide (position 2984) was changed to C, G, or T, respectively, with the compensatory nucleotide substituted at the a' position of exon 3 for in vitro splicing.
Exogenous aI2 intron transcripts having a modified EBSI sequence and/or a modified EBS2 sequence were synthesized using phage T3 polymerase and the modified plasmids as templates. The synthetic transcripts contained regions of the modified a12 intron RNA and regions of the flanking exon 2 and exon 3 of the yeast mitochondrial COXI protein. The synthetic transcripts were self-spliced and the spliced products desalted through a G-50 column, phenol-CIA extracted, ethanol precipitated, and dissolved in TE (pH8.0) at a final concentration of 1.0 pg/pl (0.52 pM).
The resulting modified, excised a12 RNA molecules were individually mixed with RNA-protein complex preparations isolated from 1 2"'D5 using the protocol described above in formulation I for RNP particle preparations. This yeast mutant has a deletion in domain V of the a12 intron and is unable to splice aI2 RNA. This mutant overproduces aI2 protein from the unspliced precursor mRNA. Thus, the RNA-protein complex preparation contains larger amounts of the aI2 protein.
For reconstitution, 1 al of the spliced, synthetic a12 transcripts was mixed with 2 pl (0.0250D 2 0 units) of the RNA-protein complex preparation and incubated on ice for 0-10 minutes.
Formulation 14 An RNP particle preparation containing an RNP particle in which the loop region of domain IV of the group II intron RNA is modified, that is the loop region nucleotide sequence of domain IV differs from the nucleotide sequence of the aI2 RNA of formulations 1-10 is prepared by two methods. First oligonucleotide-directed mutagenesis of the a12 intron DNA is performed by standard, well-known methods to change the nucleotide sequences which encode for the loop region of domain IV of the aI2 intron RNA. The mutagenized aI2 intron DNA is then inserted into a vector, such as a plasmid, where it is operably linked to an RNA polymerase promoter, such as a promoter for T7 RNA polymerase or SP6 RNA polymerase or T3 RNA polymerase and an in vitro transcript of the modified group II intron RNA is made as described above in formulation 12. The exogenous RNA is then combined with an RNA-protein complex that has been isolated as described for formulation 12 to produce a modified reconstituted RNP particle preparation.
Alternatively, an RNP particle preparation in which the sequences within the loop region of the group II intron RNA are modified is prepared by site-directed mutagenesis of an organism, such as a yeast, as described in formulations 4-10, and by isolation of the RNP particle preparation from the organism as described in formulation 1.
Formulation 15 RNP Particle Preparation from a Genetically-Engineered Cell A nucleotide integrase comprising an excised RNA which is encoded by the Ll.ltrB intron of a lactococcal cojugative element pRSO1 of Lactococcus lactis and the protein encoded by the ORFLtrA of the Ll.ltrB intron were prepared by transforming cells of the BLR(DE3) strain of the bacterium Escherichia coli, which has the recA genotype, with the plasmid pETLtrA19. Plasmid pETLtrA19 comprises the DNA sequence for the group II WO 98/38337 PCT/US98/03990 intron Ll.ltrB from Lactococcus lactis, positioned between portions of the flanking exons ItrBEl and ltrBE2.
pETLtrA19 also comprises the DNA sequence for the T7 RNA polymerase promoter and the T7 transcription terminator. The sequences are oriented in the plasmid in such a manner that the ORF sequence, SEQ. ID. NO. 6, within the Ll.ltrB intron is under the control of the T7 RNA polymerase promoter. The ORF of the Ll.ltrB intron encodes the protein ItrA. The sequence of the Ll.ltrB intron and the flanking exon sequences present in pETLtrA19 are shown SEQ.ID. NO. 5. The amino acid sequence of the ItrA protein is shown in SEQ. ID. NO.7. Domain IV is encoded by nucleotide 705 to 2572.
pETLtrA19 was prepared first by digesting pLE12, which was obtained from Dr. Gary Dunny from the University of Minnesota, with HindIII and isolating the restriction fragments on a 1% agarose gel. A 2.8 kb HindIII fragment which contains the Ll.ltrB intron together with portions of the flanking exons ItrBEl and ltrBE2 was recovered from the agarose gel and the single-stranded overhangs were filled in with the Klenow fragment of DNA polymerase I obtained from Gibco BRL, Gaithersburg, MD. The resulting fragment was ligated into plasmid pET-1 la that had been digested with Xbal and treated with Klenow fragment. pET-1 la was obtained from Novagen, Madison,
WI.
pETLtrAl9 was introduced into the E. coli cells using the conventional CaCl 2 -mediated transformation procedure of Sambrook et al. as described in "Molecular Coning A Laboratory Manual", pages 1-82, 1989 Single transformed colonies were selected on plates containing Luria-Bertani (LB) medium supplemented with ampicillin to select the plasmid and with tetracycline to select the BLR strain. One or more colonies were inoculated into 2 ml of LB medium supplemented with ampicillin and grown overnight at 37 0 C with shaking. 1 ml of this culture was inoculated into 100 ml LB medium supplemented with ampicillin and grown at 370 C with shaking at 200 rpm until of the culture reached 0.4. Then isopropyl-beta-D-thiogalactoside was added to the culture to a final concentration of I mM and incubation was continued for 3 hours. Then the entire culture was harvested by centrifugation at 2,200 x g, 4'C, for 5 minutes. The bacterial pellet was washed with 150 mM NaCI and finally resuspended in 1/20 volume of the original culture in 50 mM Tris, pH 7.5, 1 mM EDTA, 1 mM DTT, and 10% (v/v) glycerol (Buffer Bacteria were frozen at -70 0
C.
To produce a lysate the bacteria were thawed and frozen at -70 0 C three times. Then 4 volumes of 500 mM KCI, 50 mM CaCI 2 25 mM Tris, pH 7.5, and 5 mM DTT (HKCTD) were added to the lysate and the mixture was sonicated until no longer viscous, i.e. for 5 seconds or longer. The lysate was fractionated into a soluble fraction and insoluble fraction by centrifugation at 14,000 x g, 4 0 C, for 15 minutes. Then 5 ml of the resulting supernatant, i.e., the soluble fraction, were loaded onto a sucrose cushion of 1.85 M sucrose in HKCTD and centrifuged for 17 hours at 4°C, 50,0000 rpm in a Ti 50 rotor from Beckman. The pellet which contains the RNP particles was washed with 1 ml water and then dissolved in 25 pl 10 mM Tris, pH 8.0, 1 mM DTT on ice. Insoluble material was removed by centrifugation at 15,000 x g, 4 0 C, for 5 minutes. The yield of RNP particles prepared according to this method comprise the excised Ll.ltrB intron RNA and the ItrA protein.
Preparation of Substrate DNA WO 98/38337 PCT/US98/03990 Labeled DNA substrates having sequences from the E2/E3 junction of the yeast mitochondrial COX1 gene, the El/E2 junction of the yeast mitochondrial COXI gene, and the E1/E2 junction of the putative Lactococcus lactis reaxase gene (ItrB) were synthesized from recombinant plasmids or synthetic oligonucleotide templates by PCR or primer extension. The sequence of the substrate containing the E2/E3 junction of the yeast mitochondrial COX 1 gene is depicted in Figure 3 as the wt sequence. Figure 3 also identifies the locations of the mutations in this sequence. The sequence of the substrate containing the E1/E2 junction of the yeast mitochondrial COX 1 gene is depicted in Figure 6, which also identifies the locations of the mutations in this sequence. The sequence of the substrate containing the El/E2 junction of the putative Lactococcus lactis relaxase gene (ItrB) is depicted in Figure 8, which also identifies the locations of the mutations in this sequence. DNA substrates that were labeled on the 5' end of the antisense strand were also generated from plasmids by PCR with 200 ng of the 5' end-labeled primer and unlabeled primer, both of which are complementary to a sequence in the polylinker. Single-stranded DNA substrates were synthesized by end-labeling nucleotides. Short segments of double-stranded DNA substrates were also prepared The following examples of methods employing nucleotide integrases comprising an excised aI2 intron RNA bound to an aI2 protein, an excised all intron RNA bound to an all protein, or an excised ItrA intron RNA bound to an ItrA protein to cleave DNA substrates are for illustration only and are not intended to limit the scope of the invention.
Example 1 Cleaving a Double-Stranded DNA Substrate with a Nucleotide Integrase Comprising a wild-type a12 Intron RNA and a wild-type aI2-Encoded Protein 0.025 O.D.
26 0 units of the RNP particles of formulation 1 were reacted with a DNA substrate consisting of yeast mitochondrial COXI exons 2 and 3 (E2E3) and comprising the WT sequence shown in Figure 3.
The reaction was conducted at 37 0 C in a buffer containing 100 mM KC1, 20 mM MgCl 2 at pH7.5. One portion of the cleavage products was denatured with glyoxal and analyzed in a 1% agarose gel to determine the extent of cleavage of the top strand or sense strand of the DNA substrate at the E2/E3 junction. Another portion of the nucleic acid cleavage products was analyzed in a denaturing 6% polyacrylamide gel to determine the extent of cleavage of both strands of the double stranded DNA substrate. The gels were dried and autoradiographed or quantitated by phosphorimaging with a Molecular Dynamics Phosphorimager 445.
The results indicated that the nucleotide integrase comprising an excised a12 intron RNA from wildtype yeast bound to an a12 intron-encoded protein from wild-type yeast cleaved the top strand of a substrate having the wt target sequence at the position marked by the arrowhead in Figure 3. The results also indicated that the group II intron RNA is integrated into the cleavage site of the sense strand. The results also indicated that the nucleotide integrase cleaved the bottom strand or antisense strand of the double-stranded DNA substrate at a location 10 base pairs downstream from the cleavage site in the first strand.
0.025 O.D.,2 6 units of the RNP particles of formulation I were reacted with six different derivatives of the wt DNA substrate of Figure 3. Each of the derivatives contained a single point mutation in IBS2 of the wt sequence shown in Figure 3. In the derivatives, the nucleotides in the -10, -11, -12, and -13 were each changed to its complement. The reactions were conducted as and the cleavage products assayed on a 1% agarose gel WO 98/38337 PCT/US98/03990 as described above. The results indicated that the ability of this nucleotide integrase to cleave a double-stranded DNA substrate was considerably reduced unless there was full complementarity between each of the nucleotides of EBS2 of the aI2 intron RNA and each of the nucleotides of the IBS2 of the substrate. The only exception occurred with the substrate having a mutation at the nucleotide at +7.
0.025 units of the nucleotide integrase of formulation 1 were reacted with derivatives of the wt DNA substrate of Figure 3 in which the nucleotides at each of the positions from -14 to -21 in the wt sequence were separately changed to a mixture of the incorrect nucleotides. Thus, the nucleotide integrase was reacted with different substrates, each of which contained a mixture of three mutations at a single site. The reactions were conducted as described above in example 1 and the cleavage products were glyoxylated and assayed on a 1% agarose gel. The results indicated that the nucleotide integrase cleaved substrates having point mutations at position -21, -20, 17, and -14 in the target sequence at levels that ranged from 67% to 115% of the levels achieved when the nucleotide integrase was reacted with the wt sequence depicted in Figure 3. The levels of cleavage were reduced to the greatest extent with the substrates having point mutations at -15 and -18. The level of cleavage that occurred with substrates having mutations at -15 and -18 was 9% and 3% of the cleavage obtained when the nucleotide integrase was reacted with the wt sequence depicted in Figure 3. Mutations at positions -16 and -19 had moderate effects, and substrates containing these mutation were cleaved by the nucleotide integrase at levels that were 23% and 31% of the levels achieved with a substrate having the wt sequence.
0.025 O.D.
26 0 units of the nucleotide integrase of formulation I were reacted with derivatives of the DNA substrate of Figure 3 in which the nucleotides at each of the positions from +1 to +10 in the wt sequence were separately changed to a mixture of three different bases. Thus, the nucleotide integrase was reacted with 30 different substrates, each of which had a mixture of the three different nucleotides. The reactions were conducted as described above in example 1 and the cleavage products were assayed on a 6% polyacrylamide gel to determine whether the nucleotides at these positions are required for cleavage of the antisense strand of the substrate containing the wt sequence. The cleavage products were also glyoxylated and analyzed on a 1% agarose gel to determine if changes in the nucleotides at these positions had any effect on the ability of the nucleotide integrase to cleave the top strand of the substrate. The results indicated that the aI2 nucleotide integrase cleaved substrates for the second strand having changes at position and +6 at levels that were 39, 33, and 29 respectively of the levels achieved when the nucleotide integrase was reacted with the wt sequence depicted in Figure 3. Changes in the nucleotides at the other positions, and +10 had little effect on the ability of the nucleotide sequence to cleave the second strand of the substrate. The results also indicated that changes in the nucleotides at each of these positions had little effect on the ability of the nucleotide integrase to cleave the top strand of the mutated substrate.
Comparative Example A 0.025 O.D.
2 60 units of the RNP particle preparations of formulations 1, 2, 4, 5 were reacted for minutes with 125 fmoles (150,000 cpm) an internally-labeled DNA substrate having the wt sequence depicted in Figure 3. To verify cleavage, the products were glyoxalated and analyzed in a 1% agarose gel. The results indicated WO 98/38337 PCT/US98/03990 that nucleotide integrases which lack excised a12 intron RNA or in which the intron-encoded protein lacks the nonconserved portion of the Zn domain, will neither cleave the double-stranded DNA substrate nor attach an RNA.
Example 2 Cleaving a Double-stranded DNA substrate with the Reconstituted RNP Particle Preparation of Formulation 12 The reconstituted RNP particle preparation of formulation 12 was reacted with 250 fmoles (300,000 cpm) of the 142 base pair DNA substrates generated from pE2E3 and which were 5' end-labeled on either the sense strand or the antisense strand for 20 minutes at 37 0 C. To verify cleavage of both strands of the substrate, the reaction products were extracted with phenol-CIA in the presence of 0.3 M NaOAc and 2 pg single-stranded salmon sperm DNA followed by precipitation with ethanol. Reactions products were analyzed in a 6% polyacrylamide/8 M urea gel.
The results indicated that the reconstituted particle preparation cleaves both strands of a double-stranded DNA substrate which contains the wild-type sequence shown in Figure 4. Similar results, i.e. cleavage of both strands, were obtained when the 5' end labeled substrates were incubated with the RNP particle preparation of formulation Example 3 Cleaving Double-stranded DNA Substrates with a Nucleotide Integrase Comprising a Modified a12 Intron RNA and an al2-Encoded Protein.
0.025 O.D.
2 6 o units of the RNP particles of formulation 13 in which the EBSI of the aI2 group II intron RNA was changed to the EBSI sequence of the all intron RNA was reacted with the wt DNA substrate of Figure 3 and with a derivative thereof in which the nucleotides at position -1 to -6 were simultaneously changed to 5'TTAATG, which is the IBSI sequence of the wt sequence for the all nucleotide integrase. The reactions were conducted and the cleavage products analyzed as described in example 1. The results indicated that an a12 nucleotide integrase comprising a group II intron RNA with a modified EBSI was not able to cleave a substrate with the wt sequence but was able to cleave a substrate in which the nucleotides at position -1 to -6 were complementary to the modified EBS1.
Example 4 Cleaving Substrate with a Nucleotide integrase Comprising a Wild-type or Modified aI2 Intron RNA and an al2-Encoded Protein 0.025 O.D.
26 o units of the RNP particles of formulation 1 were reacted with three different derivatives of the DNA wt substrate of Figure 3. Each of the derivatives contained a single point mutation. In the derivatives the nucleotide at +1 was changed to either a C, G, or A. The derivatives were also reacted with a nucleotide integrase comprising an a12 intron RNA in which the nucleotide immediately preceding EBSI was either an A, G, C, or T. The reactions were conducted and the cleavage products assayed on a 1% agarose gel as described in example 1. The results indicated that cleavage of the top strand is enhanced when the nucleotide at +1 is complementary to the nucleotide immediately preceding the EBS1 in the a12 intron RNA and that cleavage of the sense strand is strongly reduced when the target sequence has a G at the +1 position and the intron RNA has a purine nucleotide (A or G) at the 5 position.
WO 98/38337 PCT/US98/03990 Example 5 Cleaving Double-Stranded DNA Substrates with a Nucleotide Integrase Comprising an all intron RNA and an all intron-encoded protein.
Double-stranded DNA substrates comprising either the wt sequence or an altered sequence having one of the eleven single point mutations depicted in Figure 6 were reacted with the RNP particle preparation of Formulation 3. For each reaction, 1.5 nM (150000 cpm) of a double-stranded DNA substrate was mixed with 0.025
OD
2 units of the RNP particle preparation in 10 pl of 50 mM Tris pH 7.5, 5 mM KCI, 10 mM MgCI 2 5 mM DTT.
The reaction mixtures were incubated for 20 minutes at 37 0 C. The reaction was stopped by adding 70 pl of 28.6 mM EDTA, 0.15 mg/ml tRNA. The nucleic acids were phenol extracted, ethanol precipitated, glyoxylated and analyzed on a 1% agarose gel.
The results indicated that the nucleotide integrase of formulation 3 cleaved substrate DNAs having mutations at positions -23, -20, -17, -16, -15 and -14 as efficiently as a substrate having the wt sequence depicted in Figure 6. Mutations at positions A(-19) and A(-18) reduced the efficiency of the cleavage somewhat from 75 to 25% of the cleavage that occurred with the wt sequence. The most critical nucleotide appears to be the C at position(-13). Mutations at this position reduced cleavage of the substrate to less than 1% of that which occurred with the wt sequence.
Example 6 Cleaving substrates with a Nucleotide Integrase Comprising an Ll.ltrB intron RNA and an Ll.ltrB intronencoded protein.
Double-stranded DNA substrates comprising either the wt sequence or an altered wt sequence having one of the eleven single point mutations depicted in Figure 8 were reacted with the RNP particle preparation of Formulation 15. The point mutations occur at positions -23 to -13 in the wt sequence. For each reaction, 1.5 nM of a double-stranded DNA substrate was mixed with 0.025 OD 2 6 o units of the RNP particle preparation in 10 pl of 50 mM Tris pH 7.5, 10 mM KC1, 10 mM MgCl,, 5 mM DTT. The reaction mixtures were incubated for 20 minutes at 37°C.
The reaction was stopped by adding 70 p1 of 28.6 mM EDTA, 0.15 mg/ml tRNA. The nucleic acids were phenol extracted, ethanol precipitated, glyoxylated and analyzed on a 1% agarose gel The results indicated that the nucleotide integrase of formulation 15 cleaved substrate DNAs having mutations at positions and A(-14) at levels that were approximately 80% of the levels achieved with a substrate having the wt sequence depicted in Figure 8. Substrates having point mutations at positions T(-19) were cleaved at levels that were approximately 40% or less of the levels achieved using substrates having a wt sequence.
Example 7 Cleaving a Double-Stranded DNA Substrate with Purified RNP Particles 125 fmoles (150,000 cpm) of an internally-labeled substrate containing of yeast mitochondrial COXI exons 2 and 3 (E2E3) and comprising the WT sequence shown in Figure 3 were incubated with 10 l of each of the fractions obtained from the sucrose gradient in formulation la. Taking into account the composition of the fractions, the final reaction medium of 20 pi contained 100 mM KC1, 20 mM MgC1, 50 mM Tris-HCI, pH 7.5, and 5 mM DTT.
Following a 20 minute reaction at 37 0 C, 30 pl of water, 5 pl 0.3 M NaOAc and 5 pg tRNA were added to the WO 98/38337 PCTUS98/03990 fractions. The reaction products were phenol extracted, ethanol precipitated, glyoxalated, separated on a 1% agarose gel and analyzed by autoradiography of the dried gel. The results indicated that the purified RNP particles of formulation la are useful to cleave both strands of a double-stranded DNA substrate and to insert the a12 intron RNA into the cleavage site.
Example 8 Cleaving Both Strands of a Double-stranded DNA Substrate and Attaching a cDNA to the Cleavage Site of the Antisense Strand.
0.025 O.D.
260 units of the RNP particles from formulations 1,2,4,5,6,7,8,9, were incubated with 250 fmoles (300,000 cpm) of a 142 base pair DNA substrate comprising the WT sequence shown in Figure 3. DNA incubation products were analyzed in a 6% polyacrylamide/8 M urea gel.
A radiolabeled band corresponding to the 5' fragment was detected when RNP particles of formulations 1 and 2 were incubated with substrates that had been labeled on the 5' end of either the top strand or the bottom strand of the DNA substrate, indicating that these particles cleaved both strands of the DNA substrate. The RNP particles of formulation 1 cleaved the top strand precisely at the exon 2-exon 3 junction. The RNP particles of formulations 1 and 2 cleaved the bottom or antisense strand 10 base pairs downstream from the top or sense strand cleavage site. RNP particles of formulation I that had been treated with protease K, or RNase A, or boiled did not cleave either strand.
Radiolabeled bands were also detected when the RNP particles of formulation 4 were incubated with DNA substrates that had been 5' end-labeled on either the sense strand or antisense strand, indicating that this nucleotide integrase cleaved both strands of DNA substrate. The RNP particles of formulation 4 contain a modified, excised a12 RNA and an al2-encoded protein which lacks detectable reverse transcriptase activity. Although the extent of cleavage of RNP particles of formulation 4 is somewhat reduced compared to cleavage with the RNP particle preparation of formulation 1, the endonuclease activity of the RNA is present even when the reverse transcriptase activity of the aI2-encoded protein is absent.
The radiolabeled bands were detected when the RNP particles of formulation 5 were incubated with the DNA substrate that had been labeled on the 5' end of either the top or bottom strand. In quantitative assays normalized by either O.D.
2 60 or soluble a12 reverse transcriptase activity, the cleavage activities for the top and bottom strands by the RNP particles of formulation 5 were 6% and 25%, respectively, of activities of the RNP particles of formulation 1.
A radiolabeled band corresponding to the 5' fragment was detected when the DNA substrate labeled on the 5' end of the top strand was incubated with the RNP particles of formulation 6, but a band corresponding to the fragment of the top strand was not detected when the RNP particles of formulation 6 were incubated with a DNA substrate that had been labeled on the 5' end of the bottom strand. The RNP particles of formulation 6 contain a modified, excised a12 intron RNA and an aI2-encoded protein that has an alteration in one of the putative endonuclease motifs. Similar results were obtained with the RNP particles of formulation 7, which contains a modified, excised aI2 intron RNA and an aI2-encoded protein in which the conserved portion of the Zn domain is WO 98/38337 PCT/US98/03990 absent. Likewise, RNP particles of formulations 8 and 9, each of which contains a modified, excised a12 intron RNA and an al2-encoded protein in which there is a mutation in the Zn 2 '-like motif, cleaved the sense strand but not the antisense strand of the DNA substrate. For the RNP particles of formulations 6, 7, 8, and 9, the level of sense-strand cleavage was proportional to the amount of RNA-DNA products detected in the agarose gels. These findings indicate that the antisense strand endonuclease activity of the al2-encoded protein is associated with the Zn domain.
A radiolabeled band corresponding to the 5' fragment was detected when the reconstituted RNP particle preparation of formulation 12 was incubated with substrates that had been labeled on the 5' end of either the sense strand or the antisense strand of the DNA substrate. These results establish that the reconstituted RNP particle preparation cleaves both strands of the DNA substrate.
Thus, both the catalytic RNA molecule of the nucleotide integrase and the intron-encoded protein are required for cleavage of both strands of the double stranded DNA. Certain modifications in the Zn domain and the X domain of intron-encoded protein disrupt the cleavage of the antisense strand of the nucleotide integrase 0.025 O.D.
2 6 o units of the RNP particle preparations of formulations 1, 2, 4 and 5 were combined in pl of reaction medium with 1 ug of plasmid containing the wild-type sequence depicted in Figure 4. The reaction medium contained 0.2 mM each of dATP, dGTP and dTTP, 10 pCi [a- 32 P]-dCTP (3,000 Ci/mmole; DuPont NEN, Boston, MA), 100 mM KCI, and 5 mM dithiothreitol, 2 mM MgCl,, and 50 mM Tris-HCI, pH 8.5. The reaction was initiated by addition of the RNP preparations, incubated for 10 minutes at 37 0 C, and chased with 0.2 mM dCTP for another 10 minutes. After the chase period, the reactions were terminated by extraction with phenol-CIA (phenolchloroform-isoamyl alcohol; 25:24:1) in the presence of 0.3 M sodium acetate, pH 7.8, and 5 pg E. coli tRNA carrier (Sigma, St. Louis, MO). Products were ethanol precipitated twice and resolved in 1% agarose gels containing 90 mM Tris-borate, pH 8.3, 2 mM EDTA and 0.05% ethidium bromide. The results indicated that the RNP particles of formulations 1 and 2 catalyze the formation of a DNA molecule on the cleaved DNA substrate. The results also indicated that a nucleotide integrase which lacks an excised group II intron RNA or which contains a group II intronencoded protein that lacks a reverse transcriptase domain does not catalyze the formation of a cDNA molecule on the cleaved strand.
Cleavage of single stranded DNA An aI2 nucleotide integrase comprising an excised aI2 RNA and aI2-encoded protein was used to cleave a single stranded DNA comprising an IBS2 and IBSI sequence complementary to the EBS1 and EBS2 sequences of the wild-type a12 intron RNA. The reaction is greatly improved when the 3 nucleotides +1 to +3 can base-pair with the 3 nucleotides immediately upstream of EBSI. The most preferred reaction conditions for cleavage of the substrate and insertion of the intron RNA into the cleavage site by the nucleotide integrase, are 100 mM KC1, mM MgCI 2 pH 7.5, 5 mM DTT and 37 0
C.
Claims (89)
1. A method of enhancing cleavage of a double stranded DNA substrate by a nucleotide integrase at a cleavage site, said substrate having a recognition site, said method comprising the following steps: providing a nucleotide integrase comprising; a modified group II intron RNA having a first hybridization sequence capable of hybridizing with a first intron RNA binding sequence of one strand of the DNA substrate and a second hybridization sequence capable of hybridizing with a second RNA binding sequence on said one strand of the substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 8' nucleotide on said one strand of the substrate, said 5' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein capable of binding with at least one nucleotide in a first sequence element in the recognition site of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA; providing a substrate whose recognition site comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived; and reacting the nucleotide integrase with the substrate to permit the nucleotide 20 integrase to cleave said one strand of the DNA substrate and to insert the modified group II intron RNA into the cleavage site.
2. The method of claim 1, wherein the group II intron RNA is a modified al2 intron RNA and wherein the group II intron-encoded protein is an aI2 intron-encoded protein. 25
3. The method of claim 2, wherein said one strand of the substrate comprises a T at position -13 relative to the cleavage site, a T at position -15 relative to the cleavage site, a C at position -18 relative to the cleavage site, and a G at position -16 or position 19 relative to the cleavage site.
4. The method of claim 2, wherein said one strand of said substrate comprises a 30 G at -19, a C at -18, a G at -16, a T at -15, and a T at -13 relative to the cleavage site.
The method of claim 1, wherein the group II intron RNA is a modified all o intron RNA and wherein said group II intron-encoded protein is a protein encoded by an all intron.
6. The method of claim 5, wherein said one strand of the substrate has a C at -13 relative to the cleavage site.
7. The method of claim 5, wherein said one strand of the substrate comprises a G at -22, a G at -21, an A at -19, an A at -18, and a C at -13 relative to the cleavage site.
8. The method of claim 1, wherein the nucleotide integrase comprises a modified AT', Ll.ltrB intron RNA and a protein encoded by the Ll.ltrB intron. C08506 27
9. The method of claim 8 wherein said one strand of the substrate comprises a G at -21 and an A at -20 relative to the cleavage site.
The method of claim 9, wherein said one strand of the substrate comprises a G at -21, an A at -20, a T at -19, a G at -17 and a G at -15 relative to the cleavage site.
11. A method of enhancing cleavage of a single-stranded nucleic acid substrate with a nucleotide integrase at a cleavage site comprising the following steps: providing a nucleotide integrase comprising: a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 8 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 6' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein bound to said group II intron RNA; and reacting the nucleotide integrase with the substrate to permit the nucleotide integrase to cleave the nucleic acid substrate and to insert the modified group II intron RNA into the cleavage site.
12. The method of claim 11, wherein the substrate is RNA. 20
13. The method of claim 11, wherein the substrate is a DNA.
14. The method of claim 11, wherein the nucleotide integrase is selected from a group consisting of: S(a) a modified a12 intron RNA and an a12 intron-encoded protein; a modified all intron RNA and an all intron-encoded protein; and 25 a modified Ll.ltrB intron RNA and an Ll.ltrB intron-encoded protein.
A method of enhancing cleavage of both strands of a double-stranded DNA S. substrate by a nucleotide integrase, said method comprising the following steps: providing a nucleotide integrase comprising: a modified group II intron RNA having a first hybridizing sequence 30 capable of hybridizing with a first intron RNA binding sequence on one strand of the DNA substrate and a second hybridizing sequence capable of hybridizing with a second :intron RNA binding sequence on said one strand of the DNA substrate, said modified group II intron RNA comprising a 5 nucleotide that is complementary to a 6' nucleotide on said one strand of the substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said S modified group II intron RNA; C08506 28 providing a substrate whose recognition site comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived; and reacting the nucleotide integrase with the substrate for a time and at a temperature sufficient to permit the nucleotide integrase to cleave both strands of the DNA substrate and to insert the modified group II intron RNA into the cleavage site on said one strand.
16. The method of claim 15, wherein the nucleotide integrase is selected from a group consisting of: a modified aI2 intron RNA and an aI2 intron-encoded protein; a modified all intron RNA and an all intron-encoded protein; and a modified Ll.ltr.B intron RNA and an Ll.ltrB intron-encoded protein.
17. The method of claim 15, wherein the group II intron RNA is a modified al2 intron RNA, wherein the group II intron-encoded protein is an aI2 intron-encoded protein; and wherein said one strand of the substrate comprises a C at -18, a T at 15, a T at -13, a G at -13 or -16, a T at a T at +4 and a G at +4.
18. The method of claim 15, wherein the group II intron RNA is a modified all intron RNA: wherein the group II intron-encoded protein is a protein encoded by an all intron; and wherein said one strand of the substrate comprises a C at -13, a T at a T at 20 aT at aT at an A at aG at aT at and an A at +8.
.19. The method of claim 15, wherein the group II intron RNA is a modified Ll.ltrB intron RNA and the group II intron-encoded protein is a protein encoded by an SLl.ltrB intron; and wherein the top strand of the substrate comprises a G at -21, an A aC at an A at aT at an A at aT at aC at an A at and aT at +8. 25
20. The method of claim 15, wherein the group II intron encoded protein comprises a reverse transcriptase domain, and wherein the nucleotide integrase and the substrate are reacted in a reaction mixture comprising dATP, dGTP, dTTP, and dCTP such that a cDNA molecule is formed in the cleavage site on the other strand of the DNA substrate.
21. A reconstituted nucleotide integrase preparation for enhanced cleavage of a nucleic acid substrate at a cleavage site, said preparation comprising: a modified group II intron RNA having a first hybridization sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridization sequence capable of hybridizing with a second RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 8' nucleotide on said nucleic acid substrate, said nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein; C08506 29 (iii) a reconstituted nucleotide integrase that cleaves a nucleic acid substrate at a specific site, said group II intron-encoded protein being bound to said modified group II intron RNA.
22. The reconstituted nucleotide integrase preparation of claim 21, wherein the substrate is RNA.
23. The reconstituted nucleotide integrase preparation of claim 21, wherein the substrate is DNA.
24. The reconstituted nucleotide integrase preparation of claim 23, wherein the first hybridization sequence of the modified group II intron RNA is capable of hybridizing 0o with a first intron RNA binding sequence of one strand of the DNA substrate and the second hybridization sequence is capable of hybridizing with a second RNA binding sequence on said one strand of the substrate, and wherein the 6 nucleotide of said modified group II intron RNA is complementary to a 8' nucleotide on said one strand of the substrate.
25. The reconstituted nucleotide integrase preparation of claim 23 or claim 24, wherein said substrate is double stranded, and said nucleotide integrase preparation is capable of cleaving both strands of the DNA substrate.
26. The reconstituted nucleotide integrase preparation of any one of claims 21 to 25, wherein the substrate has a recognition site which comprises a sequence which is 20 different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived and the group II intron-encoded protein is capable of binding with at least one nucleotide in a first sequence element in the recognition site of the substrate.
27. The reconstituted nucleotide integrase preparation of any one of claims 21 to 25 26, wherein the group II intron RNA is a modified aI2 intron RNA and wherein the group II intron-encoded protein is an aI2 intron-encoded protein.
28. The reconstituted nucleotide integrase preparation of claim 27, wherein said substrate comprises a T at position -13 relative to the cleavage site, a T at position Srelative to the cleavage site, a C at position -18 relative to the cleavage site, and a G at position -16 or position -19 relative to the cleavage site.
29. The reconstituted nucleotide integrase preparation of claim 27, wherein said substrate comprises a G at -19, a C at -18, a G at -16, a T at -15, and a T at -13 relative to the cleavage site.
C08506 The reconstituted nucleotide integrase preparation of any one of claims 21 to 26, wherein the group II intron RNA is a modified all intron RNA and wherein said group II intron-encoded protein is a protein encoded by an all intron.
31. The reconstituted nucleotide integrase preparation of claim 30, wherein said substrate has a C at -13 relative to the cleavage site.
32. The reconstituted nucleotide integrase preparation of claim 30, wherein said substrate comprises a G at -22, a G at -21, an A at -19, an A at -18, and a C at -13 relative to the cleavage site.
33. The reconstituted nucleotide integrase preparation of any one of claims 21 to 0o 26, wherein the nucleotide integrase comprises a modified Ll.ltrB intron RNA and a protein encoded by the Ll.ltrB intron.
34. The reconstituted nucleotide integrase preparation of claim 33, wherein said substrate comprises a G at -21 and an A at -20 relative to the cleavage site.
The reconstituted nucleotide integrase preparation of claim 33, wherein said one strand of the substrate comprises a G at -21, an A at -20, a T at -19, a G at -17 and a G at -15 relative to the cleavage site.
36. A method for making a reconstituted nucleotide integrase preparation for :enhanced cleavage of a nucleic acid substrate at a cleavage site, said method comprising the following steps: providing an exogenous RNA molecule which comprises a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 8 nucleotide that is 25 complementary to a 6' nucleotide on said nucleic acid substrate, said 6' nucleotide being located at position +1 relative to the cleavage site; providing an RNA-protein complex comprising: a group II intron-encoded protein capable of binding to at least one .nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA, said protein comprising an X domain and a Zn domain; and (ii) RNA that is free of group II intron RNA having a sequence that encodes said protein; and C08506 31 combining said exogenous RNA with said RNA-protein complex to form a reconstituted nucleotide integrase preparation.
37. The method of claim 36, wherein the substrate is RNA.
38. The method of claim 36, wherein the substrate is DNA.
39. The method of claim 38, wherein the first hybridization sequence of the modified group II intron RNA is capable of hybridizing with a first intron RNA binding sequence of one strand of the DNA substrate and the second hybridization sequence is capable of hybridizing with a second RNA binding sequence on said one strand of the substrate, and wherein the 8 nucleotide of said modified group II intron RNA is o0 complementary to a 6' nucleotide on said one strand of the substrate.
The method of claim 38 or claim 39, wherein said wherein said substrate is double stranded, and said nucleotide integrase is capable of cleaving both strands of the DNA substrate.
41. The method of any one of claims 36 to 40, wherein the substrate has a recognition site which comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived and the group II intron-encoded protein is capable of binding with at least one nucleotide in a first sequence element in the recognition site of the substrate.
42. The method of any one of claims 36 to 41, wherein the group II intron RNA is 20 a modified aI2 intron RNA and wherein the group II intron-encoded protein is an al2 intron-encoded protein.
43. The method of claim 42, wherein said substrate comprises a T at position -13 relative to the cleavage site, a T at position -15 relative to the cleavage site, a C at position -18 relative to the cleavage site, and a G at position -16 or position -19 relative to the 25 cleavage site.
44. The method of claim 42, wherein said substrate comprises a G at-19, aC at 18, a G at -16, a T at -15, and a T at -13 relative to the cleavage site. S•
45. The method of any one of claims 36 to 41, wherein the group II intron RNA is a modified all intron RNA and wherein said group II intron-encoded protein is a protein encoded by an all intron.
46. The method of claim 45, wherein said substrate has a C at -13 relative to the cleavage site.
47. The method of claim 45, wherein said substrate comprises a G at -22, a G at 21, an A at -19, an A at -18, and a C at -13 relative to the cleavage site. C08506 32
48. The method of any one of claims 36 to 41, wherein the nucleotide integrase comprises a modified Ll.ltrB intron RNA and a protein encoded by the Ll.ltrB intron.
49. The method of claim 48, wherein said substrate comprises a G at -21 and an A at -20 relative to the cleavage site.
50. The method of claim 48, wherein said substrate comprises a G at -21, an A at a T at -19, a G at -17 and a G at -15 relative to the cleavage site.
51. A method for making a reconstituted nucleotide integrase preparation for enhanced cleavage of a nucleic acid substrate at a cleavage site, said method comprising the following steps: providing an exogenous RNA molecule which comprises a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 8 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; providing an RNA-protein complex comprising: a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence S 20 element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA, said protein comprising an X domain and a Zn domain; and (ii) RNA that is free of group II intron RNA having a sequence that encodes said protein; and 25 combining said exogenous RNA with said RNA-protein complex to form a o° reconstituted nucleotide integrase preparation; said method being substantially as hereinbefore described with reference to any one of the examples but excluding reference to any comparative examples.
52. A reconstituted nucleotide integrase preparation made by the method of any 30 one of claims 36 to 51.
53. A reconstituted nucleotide integrase preparation for enhanced cleavage of a nucleic acid substrate at a cleavage site, said preparation comprising: a modified group II intron RNA having a first hybridization sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridization sequence capable of hybridizing with a second RNA binding eequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 C08506 33 nucleotide that is complementary to a 8' nucleotide on said nucleic acid substrate, said 6' nucleotide being located at position +1 relative to the cleavage site; and (ii) a group II intron-encoded protein; (iii) a reconstituted nucleotide integrase that cleaves a nucleic acid substrate at a specific site, said group II intron-encoded protein being bound to said modified group II intron RNA; and said preparation being substantially as hereinbefore described with reference to any one of the examples but excluding reference to any comparative examples.
54. A reconstituted RNP particle for enhanced cleavage of a nucleic acid substrate at a cleavage site, said particle comprising: a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 8' nucleotide on the substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; and a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II 20 intron RNA. The reconstituted RNP particle of claim 54, wherein the substrate is RNA.
55. The reconstituted RNP particle of claim 54, wherein the substrate is RNA.
56. The reconstituted RNP particle of claim 54, wherein the substrate is DNA. S:
57. The reconstituted RNP particle of claim 56, wherein the first hybridization sequence of the modified group II intron RNA is capable of hybridizing with a first intron 25 RNA binding sequence of one strand of the DNA substrate and the second hybridization sequence is capable of hybridizing with a second RNA binding sequence on said one ostrand of the substrate, and wherein the 6 nucleotide of said modified group II intron RNA is complementary to a 6' nucleotide on said one strand of the substrate.
58. The reconstituted RNP particle of claim 56 or claim 57, wherein said substrate 30 is double stranded, and said nucleotide integrase is capable of cleaving both strands of the DNA substrate.
59. The reconstituted RNP particle of any one of claims 54 to 58, wherein the substrate has a recognition site which comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived and the group II intron-encoded protein is capable of C08506 34 binding with at least one nucleotide in a first sequence element in the recognition site of the substrate.
The reconstituted RNP particle of any one of claims 54 to 59, wherein the group II intron RNA is a modified aI2 intron RNA and wherein the group II intron- encoded protein is an aI2 intron-encoded protein.
61. The reconstituted RNP particle of claim 60, wherein said substrate comprises a T at position -13 relative to the cleavage site, a T at position -15 relative to the cleavage site, a C at position -18 relative to the cleavage site, and a G at position -16 or position 19 relative to the cleavage site.
62. The reconstituted RNP particle of claim 61, wherein said substrate comprises a G at -19, a C at -18, a G at -16, a T at -15, and a T at -13 relative to the cleavage site.
63. The reconstituted RNP particle of any one of claims 54 to 59, wherein the group II intron RNA is a modified all intron RNA and wherein said group II intron- encoded protein is a protein encoded by an all intron.
64. The reconstituted RNP particle of claim 63, wherein said substrate has a C at 13 relative to the cleavage site.
The reconstituted RNP particle of claim 63, wherein said substrate comprises a G at -22, a G at -21, an A at -19, an A at -18, and a C at -13 relative to the cleavage site.
66. The reconstituted RNP particle of any one of claims 54 to 59, wherein the 20 nucleotide integrase comprises a modified Ll.ltrB intron RNA and a protein encoded by the Ll.ltrB intron.
67. The reconstituted RNP particle of claim 66, wherein said substrate comprises a G at -21 and an A at -20 relative to the cleavage site.
68. The reconstituted RNP particle of claim 66, wherein said substrate comprises a 25 G at -21, an A at -20, a T at -19, a G at -17 and a G at -15 relative to the cleavage site.
69. A method for making a reconstituted RNP particle for enhanced cleavage of a nucleic acid substrate at a cleavage site, said method comprising the following steps: providing an exogenous RNA molecule which comprises a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 6 nucleotide that is complementary to a 8' nucleotide on said nucleic acid substrate, said 5' nucleotide being located at position +1 relative to the cleavage site; S(b) providing an RNA-protein complex comprising: C08506 a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA, said protein comprising an X domain and a Zn domain; and (ii) RNA that is free of group II intron RNA having a sequence that encodes said protein; and combining said exogenous RNA with said RNA-protein complex to form a reconstituted RNP particle.
70. The method of claim 69, wherein the substrate is RNA.
71. The method of claim 69, wherein the substrate is DNA.
72. The method of claim 71, wherein the first hybridization sequence of the modified group II intron RNA is capable of hybridizing with a first intron RNA binding sequence of one strand of the DNA substrate and the second hybridization sequence is capable of hybridizing with a second RNA binding sequence on said one strand of the substrate, and wherein the 8 nucleotide of said modified group II intron RNA is complementary to a 6' nucleotide on said one strand of the substrate.
73. The method of claim 71 or claim 72, wherein said substrate is double stranded, and said nucleotide integrase is capable of cleaving both strands of the DNA substrate. 20
74. The method of any one of claims 69 to 73, wherein the substrate has a recognition site which comprises a sequence which is different from the sequence of the recognition site for the wild-type group II intron from which the modified group II intron RNA was derived and the group II intron-encoded protein is capable of binding with at least one nucleotide in a first sequence element in the recognition site of the substrate. 25
75. The method of any one of claims 69 to 74, wherein the group II intron RNA is a modified aI2 intron RNA and wherein the group II intron-encoded protein is an al2 intron-encoded protein.
76. The method of claim 75, wherein said substrate comprises a T at position -13 relative to the cleavage site, a T at position -15 relative to the cleavage site, a C at position -18 relative to the cleavage site, and a G at position -16 or position -19 relative to the cleavage site.
77. The method of claim 75, wherein said substrate comprises a G at -19, a C at 18, a G at -16, a T at -15, and a T at -13 relative to the cleavage site. C08506 36
78. The method of any one of claims 69 to 74, wherein the group II intron RNA is a modified all intron RNA and wherein said group II intron-encoded protein is a protein encoded by an all intron.
79. The method of claim 78, wherein said substrate has a C at -13 relative to the cleavage site.
The method of claim 78, wherein said substrate comprises a G at -22, a G at 21, an A at -19, an A at -18, and a C at -13 relative to the cleavage site.
81. The method of any one of claims 69 to 74, wherein the nucleotide integrase comprises a modified Ll.ltrB intron RNA and a protein encoded by the Ll.ltrB intron.
82. The method of claim 81, wherein said substrate comprises a G at -21 and an A at -20 relative to the cleavage site.
83. The method of claim 81, wherein said substrate comprises a G at -21, an A at a T at -19, a G at -17 and a G at -15 relative to the cleavage site.
84. A method for making a reconstituted RNP particle for enhanced cleavage of a nucleic acid substrate at a cleavage site, said method comprising the following steps: providing an exogenous RNA molecule which comprises a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence *4 capable of hybridizing with a second intron RNA binding sequence on said nucleic acid 20 substrate, said modified group II intron RNA comprising a 8 nucleotide that is complementary to a 6' nucleotide on said nucleic acid substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; providing an RNA-protein complex comprising: a group II intron-encoded protein capable of binding to at least one 25 nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA, said protein comprising an X domain and a Zn domain; and (ii) RNA that is free of group II intron RNA having a sequence that encodes said protein; and combining said exogenous RNA with said RNA-protein complex to form a reconstituted RNP particle; said method being substantially as hereinbefore described with reference to any one of the examples but excluding reference to any comparative examples. N
85. A reconstituted RNP particle made by the method of any one of claims 69 to C08506
86. A reconstituted RNP particle for enhanced cleavage of a nucleic acid substrate at a cleavage site, said particle comprising: a modified group II intron RNA having a first hybridizing sequence capable of hybridizing with a first intron RNA binding sequence on the nucleic acid substrate and a second hybridizing sequence capable of hybridizing with a second intron RNA binding sequence on said nucleic acid substrate, said modified group II intron RNA comprising a 8 nucleotide that is complementary to a 8' nucleotide on the substrate, said 8' nucleotide being located at position +1 relative to the cleavage site; and a group II intron-encoded protein capable of binding to at least one nucleotide in a first sequence element and to at least one nucleotide in a second sequence element of the substrate, said group II intron-encoded protein being bound to said modified group II intron RNA; and said particle being substantially as hereinbefore described with reference to any one of the examples but excluding reference to any comparative examples.
87. A method of cleaving a nucleic acid substrate at a cleavage site, said method comprising reacting a reconstituted nucleotide integrase preparation of any one of claims 21 to 35, 52 or 53, or a reconstituted RNP particle of any one of claims 54 to 68, 85 or 86 with the nucleic acid substrate to permit the nucleotide integrase to cleave said nucleic acid substrate and to insert the modified group II intron RNA into the cleavage site. 20
88. A method of cleaving a nucleic acid substrate, as defined in any one of claims i. 1, 11, 15 or 87, substantially as hereinbefore described with reference to any one of the examples but excluding reference to any comparative examples. So.
89. The method of claim 87 or 88, wherein the substrate is RNA. 0*OS The method of claim 87 or 88, wherein the substrate is DNA. 25 91. The method of claim 87 or 88, wherein the substrate is double stranded DNA. Dated 22 March 2002 a OHIO STATE RESEARCH FOUNDATION 0 Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON C08506
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3922097P | 1997-02-28 | 1997-02-28 | |
| US60/039220 | 1997-02-28 | ||
| US7616198P | 1998-02-26 | 1998-02-26 | |
| US60/076161 | 1998-02-26 | ||
| PCT/US1998/003990 WO1998038337A1 (en) | 1997-02-28 | 1998-02-27 | Methods for cleaving dna with nucleotide integrases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6676298A AU6676298A (en) | 1998-09-18 |
| AU748237B2 true AU748237B2 (en) | 2002-05-30 |
Family
ID=26715924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU66762/98A Ceased AU748237B2 (en) | 1997-02-28 | 1998-02-27 | Methods for cleaving DNA with nucleotide integrases |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0996742A4 (en) |
| AU (1) | AU748237B2 (en) |
| CA (1) | CA2282737A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592161B2 (en) | 1999-10-15 | 2009-09-22 | The Ohio State University Research Foundation | Methods for analyzing the insertion capabilities of modified group II introns |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010362A1 (en) * | 1995-09-12 | 1997-03-20 | The Ohio State Research Foundation | Methods of using nucleotide integrase for cleaving dna and attaching nucleic acids |
-
1998
- 1998-02-27 EP EP98908823A patent/EP0996742A4/en not_active Withdrawn
- 1998-02-27 CA CA002282737A patent/CA2282737A1/en not_active Abandoned
- 1998-02-27 AU AU66762/98A patent/AU748237B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010362A1 (en) * | 1995-09-12 | 1997-03-20 | The Ohio State Research Foundation | Methods of using nucleotide integrase for cleaving dna and attaching nucleic acids |
Non-Patent Citations (2)
| Title |
|---|
| SALDANHA ET AL FASEB (1993) 7 PP 15-24 * |
| YANG ET AL NATURE (1996) 381 PP 332-5 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592161B2 (en) | 1999-10-15 | 2009-09-22 | The Ohio State University Research Foundation | Methods for analyzing the insertion capabilities of modified group II introns |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2282737A1 (en) | 1998-09-03 |
| EP0996742A1 (en) | 2000-05-03 |
| AU6676298A (en) | 1998-09-18 |
| EP0996742A4 (en) | 2006-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021231074C1 (en) | Class II, type V CRISPR systems | |
| EP0851940B1 (en) | Methods of using nucleotide integrase for cleaving dna and attaching nucleic acids | |
| EP3292219B9 (en) | Methods and kits for fragmenting dna | |
| AU716362B2 (en) | Compositions and methods to promote homologous recombination in eukaryotic cells and organisms | |
| CN106715694B (en) | Nuclease-mediated DNA Assembly | |
| WO2020168234A1 (en) | Enzymes with ruvc domains | |
| CN111699254A (en) | Genome editing in corynebacterium using CRISPR | |
| US5804418A (en) | Methods for preparing nucleotide integrases | |
| CN117083379A (en) | Peptide fusions or conjugates for gene editing | |
| WO1999043854A1 (en) | Methods for cleaving single-stranded and double-stranded dna substrates with nucleotide integrase | |
| US5792633A (en) | Process for gene targeting and genome manipulations | |
| WO1998038337A1 (en) | Methods for cleaving dna with nucleotide integrases | |
| Rinckel et al. | Influences of Histone Stoichiometry on the Target Site Preference of Retrotransposons Ty 1 and Ty 2 in Saccharomyces cerevisiae | |
| AU748237B2 (en) | Methods for cleaving DNA with nucleotide integrases | |
| US20020086323A1 (en) | Methods for cleaving single-stranded and double-stranded DNA substrates with nucleotide integrase | |
| CA2271228A1 (en) | Method for producing tagged genes, transcripts and proteins | |
| JP2024509048A (en) | CRISPR-related transposon system and its usage | |
| US20250179452A1 (en) | Systems and methods for transposing cargo nucleotide sequences | |
| AU739106B2 (en) | Methods of making an RNP particle having nucleotide integrase activity | |
| US20090142838A1 (en) | Methods for expressing rnp particles in eukaryotic cells | |
| JP2002515759A (en) | DNA cleavage method using nucleotide integrase | |
| Twyman | Recombinant DNA and molecular cloning | |
| JP2025508794A (en) | Fusion proteins | |
| WO2002036830A2 (en) | Method of determining gene copy number | |
| HK40061002B (en) | Pacas9 nuclease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTORS TO READ GEORG MOHR AND INCLUDE HUATAO GUO |
|
| FGA | Letters patent sealed or granted (standard patent) |